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Abstract 
Highly variable synthetic routes were elaborated toward trisubstituted C-glycopyranosyl 
1,2,4-triazoles. N-Acyl-thioamide derivatives were obtained by acylation of O-perbenzoylated 
2,6-anhydro-D-glycero-D-gulo-heptonothioamide by acid chlorides and of thioamides by O-
perbenzoylated 2,6-anhydro-D-glycero-D-gulo-heptonoyl chloride. These precursors reacted 
with substituted hydrazines in a regioselective manner to yield 3-β-D-glucopyranosyl-1,5-
disubstituted- and 5-β-D-glucopyranosyl-1,3-disubstituted-1,2,4-triazoles, respectively. 
Analogous N-acyl-2,6-anhydro-heptonamides failed to give the above triazoles with 
hydrazines. O-Deprotection of the C-glucosyl 1,2,4-triazoles by the Zemplén method 
furnished test compounds which showed no inhibition against rabbit muscle glycogen 
phosphorylase b. 
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Introduction 
Although 1,2,4-triazoles have not been found as constituents of natural compounds, this 
heterocycle is frequently part of biologically active synthetic molecules, among them a wide 
range of marketed drugs and agricultural chemicals, and finds various applications in many 
other fields, e.g. in synthetic and analytical chemistry, uses as corrosion inhibitors, ligands of 
metal complexes, and functional materials. As a consequence of this broad utility and interest, 
a large variety of synthetic methods have been elaborated to get this heteroring and its 
derivatives resulting in miriads of 1,2,4-triazole containing compounds.1-8 
Carbohydrate derivatives of this heterocycle are much less available. Direct conjugation of the 
1,2,4-triazole ring with sugars may occur by a C-N or a C-C bond. From the former class 
several examples of bioactive nucleoside analogues9 and N1-10-13 as well as N4-
glycopyranosides14 have been known. C-Glycosyl 1,2,4-triazoles are an even more 
uncommon type15-18 and only in recent years has progress been made in this field with the 
syntheses of 3-glycopyranosyl-5-substituted-1,2,4-triazoles as glycogen phosphorylase 
inhibitors for potential antidiabetic use.19-24 
As a continuation of our efforts in the above syntheses, the preparation of trisubstituted C-
glycopyranosyl 1,2,4-triazoles was envisaged to generate molecules for structure‒activity 
relationships of glycogen phosphorylase inhibitors and also for other potential biological 
applications. From the three possible isomeric structures (Scheme 1) some examples of the 3-
glycosyl-4,5-disubstituted-1,2,4-triazoles (I) were already described,21 therefore, this work 
has focused on the 3-β-D-glucopyranosyl-1,5-disubstituted (II) and 5-β-D-glucopyranosyl-1,3-
disubstituted (III) counterparts. 
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Results and Discussion 
A retrosynthetic analysis of the target compounds (Scheme 1) revealed two types of synthetic 
possibilities. Type A syntheses would require a 1,3-dipolar cycloaddition of nitriles with 
nitrilimines. Toward triazoles II route A would require a series of nitriles IV which 
themselves may also have to be prepared from other kinds of starting materials and C-
glycosyl nitrilimine precursors with appropriate substituents like 5-glycosyl-2-substituted-
tetrazoles V or hydrazonoyl halide derivatives of anhydro-aldonic acids VI which are also not 
readily available. Toward triazoles III route A would need well known glycosyl cyanides X 
and nitrilimine precursors such as 2,5-disubstituted-tetrazoles XI or hydrazonoyl halides XII. 
Actually, the latter type reaction (X + XII) was studied to some extent, and a few 3-β-D-
glycopyranosyl-1,5-disubstituted-1,2,4-triazoles were described.16,17 However, for getting a 
large series of compounds, multistep synthesis of each hydrazonoyl halide and/or 2,5-
disubstituted-tetrazole would be necessary. These requirements adumbrate rather labour 
intensive preparative work to get the precursors for both route A type syntheses. Therefore we 
turned to type B synthetic pathways which would need various hydrazines VII and acylation 
of easily available C-glycosyl formamides (anhydro-aldonamides) to get precursors VIII. In 
these cases the regioselectivity may be a challenge due to the possibly similar reactivity of the 
two electrophilic centres of VIII, therefore, the related acyl-thioamides IX and XIII were also 
taken into consideration.  
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Synthesis realized by the transformation 
of O-peracylated 5-glycosyl tetrazoles 
with imidoyl chlorides.21 
 
 
 
 
 
Scheme 1. Isomers of trisubstituted C-glycopyranosyl 1,2,4-triazoles (I-III) and retrosynthetic analysis 
of the target compounds II and III. 
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To get precursors of type VIII, the acylation of O-perbenzoylated 2,6-anhydro-heptonamide 
(C-β-D-glucopyranosyl formamide) 125 was studied (Scheme 1). Under some conditions (1.5-
15 equiv. of Ac2O in the presence of N-bases,
26,27 or 1-2 equiv. of AcCl the presence of 1.2 
equiv of NaH in THF,28,29 2.5 equiv. of Bz2O with catalytic H2SO4 in CHCl3 at reflux 
temperature30) incomplete conversion of the starting 1 was observed. Full transformation of 1 
was achieved however, by using 5 equiv. of both an acid chloride and pyridine in CHCl3 at r. 
t. (Table 1), but the products 2-4 were accompanied by significant amounts of diacylated 
derivatives 5-7, respectively, and in the cases of aromatic acid chlorides, the dehydration31 of 
1 to give glucosyl cyanide 825 (cf also Scheme 3) was the main reaction pathway. 
 
 
Table 1. Experiments towards acylation of 2,6-anhydro-heptonamide 1 
 
 
i) 5 equiv. RCOCl, 5 equiv. pyridine, dry CHCl3, rt 
R Yield (%) 
Me 2  (51) 5 (34) - 
Ph 3  (26) 6   (8) 8  (67) 
1-Naphthyl 4  (16) 7 (15) 8  (39) 
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An initial experiment towards the formation of a 1,2,4-triazole was carried out by reacting 2 
with hydrazine hydrate or hydrazinium acetate. Surprisingly, the products of this 
transformation, obtained after column chromatography with an acetone-hexane eluent, proved 
to be amide 1 and acylhydrazone 10 (Scheme 2). This experiment proved the similar 
reactivity of the two N-carbonyls in 2 (the appearance of 10 can be explained by the formation 
of 9 which was condensed with acetone during the purification). Under the same conditions 
monoacyl-amides 3 and 4 gave only 10 as the final product in 74 and 72 % yields, 
respectively. These observations indicated that N-acyl-amides 2-4 could not serve as starting 
materials for the planned 1,2,4-triazole syntheses. 
 
Scheme 2.  
 
After this failure we turned to the preparation of precursors IX and XIII (Scheme 3). Towards 
IX, the N-acylation of 2,6-anhydro-aldonothioamide (C-β-D-glucopyranosyl thioformamide) 
1132 was smoothly carried out by several aliphatic acid chlorides to give excellent yields of 
12-15. Unexpectedly, attempts to acylate 11 by aromatic acid chlorides (PhCOCl, 1-
naphthoylchloride) gave glucosyl cyanide 825 as the main product. Each reaction mixture 
contained a second product, probably the N-aroyl-thioamide, however, this could not be 
isolated in a pure state. This observation turned out to have a literature precedent,33 and thus, 
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the formation of 8 as the primary product could be explained by an S-aroylation of the CSNH2 
moiety to give 16 (X = S) which then underwent a spontaneous loss of ArCOSH. Formation 
of 8 in N-aroylations of 1 (Table 1) can be explained in an analogous manner via 16 (X = O). 
Precursors of type XIII were obtained by glycosylcarbonylation of thioacetamide and 
thiobenzamide with 2,6-anhydro-aldonoyl chloride (C-β-D-glucopyranosylformyl chloride) 
1720,34 and the expected 18 and 19, respectively, could be isolated in acceptable yields 
(Scheme 3). 
 
 
Scheme 3. Reagents and conditions: i) 1.5 equiv. RCOCl, 1.5 equiv. pyridine, dry CHCl3, rt; 
ii) 2 equiv. RCSNH2, 2 equiv. pyridine, dry CH3CN, rt. 
 
With the N-acyl-thioamide precursors in hand, the syntheses of the target 1,2,4-triazoles were 
carried out. Compounds 12-15 were reacted with hydrazinium acetate in pyridine at r. t. 
(Table 2) to give 20, 24, 27 and 30, respectively, from which the first three were identical, 
when compared, with previously prepared compounds,20 thereby proving the suitability of 
these precursors for the triazole synthesis. Reactions of 12-15 with substituted hydrazines 
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(phenylhydrazine, 2-hydroxyethyl-hydrazine and tosylhydrazine) gave the corresponding 21-
23, 25, 26, 28, 29, 31, and 32, respectively, in good yields. O-Debenzoylation of 21, 22, 24, 
25, 27-31 by the Zemplén method gave 3-β-D-glucopyranosyl-1,5-disubstituted-1,2,4-
triazoles 33-41, respectively, in good yields.  
Reactions of N-acyl-thioamides 18 and 19 with hydrazinium acetate gave the known 3-β-D-
glucopyranosyl-5-substituted-1,2,4-triazoles20 20 and 43, respectively (Table 3). With 
substituted hydrazines the expected 1,2,4-triazoles 42, 44-47 were obtained in varying yields, 
which were O-deprotected by the Zemplén protocol to give 5-β-D-glucopyranosyl-1,3-
disubstituted-1,2,4-triazoles 48-52, respectively, in excellent yields. When 19 was 
transformed with tosylhydrazine, triazole 43 was isolated indicating spontaneous loss of the 
tosyl moiety under the applied conditions similarly to the observations made in reactions of 
N1-tosyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamidrazone and acid 
chlorides.20 
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Table 2. Synthesis of 3-β-D-glucopyranosyl-1,5-disubstituted-1,2,4-triazoles 
 
Starting 
compound 
  Yield (%) 
 R R’ R’’ = Bz R’’ = H 
12 Me H 20a (55) - 
  Ph 21 (67) 33 (70) 
  C2H4OH 22 (70) 34 (72) 
  Ts 23a (63) - 
13 AcOCH2 H 24
a (92) - 
  Ph 25 (70) 
35 (84)  
R = CH2OH 
  C2H4OH 
26 (65) 
R = CH2OH 
36 (62) 
R = CH2OH 
14 tBu H 27a (79) - 
  Ph 28 (66) 37 (50) 
  C2H4OH 29 (65) 38 (65) 
15 Bn H 30 (75) 39 (45) 
  Ph 31 (71) 40 (70) 
  C2H4OH 32 (90) 41 (51) 
a The compound was identical with the one obtained from N1-tosyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)formamidrazone and the corresponding acid chloride.20 
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Table 3. Synthesis of 5-β-D-glucopyranosyl-1,3-disubstituted-1,2,4-triazoles 
 
Starting 
compound 
  Yield (%) 
 R R’ R’’ = Bz R’’ = H 
18 Me H 20a (57) - 
  Ph 42 (65) 48 (96) 
19 Ph H 43a (35) - 
  Ph 44 (90) 49 (83) 
  C2H4OH 45 (90) 50 (98) 
  tBu 46 (60) 51 (99) 
  3-Cl-C6H4 47 (72) 52 (99) 
  Ts (in the hydrazine) 
43a (62) 
(R’=H) 
- 
a The compound was identical with the one obtained from N1-tosyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)formamidrazone and the corresponding acid chloride.20 
 
The different reactivity of the C=O and C=S moieties in the N-acyl-thioamides leaves not 
much doubt about the regioselectivity of the above ring closing reactions, i. e. the more 
nucleophilic terminal nitrogen of the substituted hydrazine reagent reacts with the more 
electrophilic C=S group, it was found appropriate to prove this at least in one case. Thus, 
nuclear Overhauser effects (NOE) were measured in isomeric triazoles 33 and 48 (Figure 1) 
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to show the vicinity of the Me and Ph groups in the former and that of the H-1 and Ph in the 
latter.  
 
 
Figure 1. Evidence of the isomeric structures for 1,2,4-triazoles 33 and 48 
 
The unprotected compounds 33-41 and 48-52 were assayed against rabbit muscle glycogen 
phosphorylase b (RMGPb) as described before,35 however, none of them showed inhibition in 
625 µM concentration. In our previous studies19,21 several 3-glucopyranosyl-5-substituted-
1,2,4-triazoles were found active against RMGPb in the submicromolar range. The good 
inhibitory effect of those compounds was attributed to the hydrogen bond donor ability of the 
heterocycle, a feature discussed in a recent review.18 In the context of structure-activity 
relationships of GP inhibitors, the present results underline the importance of the H-bridge 
formation since this possibility is absent in the trisubtituted 1,2,4-triazoles. Furthermore, the 
additional substituent of the triazole ring may also impede binding of these molecules to the 
active site of the enzyme.   
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In conclusion, reactions of substituted hydrazines and sugar derived N-acyl-thioamide type 
precursors facilitate versatile syntheses of 3-β-D-glucopyranosyl-1,5-disubstituted- and 5-β-D-
glucopyranosyl-1,3-disubstituted-1,2,4-triazoles. The only limitation of the method is that in 
the 3-β-D-glucopyranosyl-1,5-disubstituted isomers no aromatic substituent can be introduced 
in the 5-position due to facile desulfuration of the corresponding 2,6-anhydro-
aldonothioamide by aromatic acid chlorides. 
 
Experimental 
General Methods 
Melting points were measured on a Kofler hot-stage and are uncorrected. Optical rotations 
were determined with a Perkin-Elmer 241 polarimeter at rt. NMR spectra were recorded with 
Bruker 360 (360/90 MHz for 1H/13C) or Bruker 400 (400/100 MHz for 1H/13C) spectrometers. 
Chemical shifts are referenced to the internal TMS (1H), or to the residual solvent signals 
(13C). Mass spectra were obtained by a Thermo Scientiﬁc LTQ XL instrument or by a Bruker 
micrOTOF-Q instrument. TLC was performed on DC-Alurolle Kieselgel 60 F254 (Merck), and 
the plates were visualised under UV light and by gentle heating (generally no spray reagent 
was used but, if more intense charring was necessary, the plate was sprayed with the 
following solution: abs. EtOH (95 mL), ccH2SO4 (5 mL) anisaldehyde (1 mL)). For column 
chromatography Kieselgel 60 (Merck, particle size 0.063-0.200 mm) was used. MeCN and 
CHCl3 were distilled from P4O10 and stored over 4 Å molecular sieves. Pyridine was distilled 
from KOH and stored over KOH pellets. MeOH was purified by distillation after refluxing for 
a couple of hours with magnesium turnings and iodine. Organic solutions were dried over 
anhydrous MgSO4 and concentrated under diminished pressure at 40 ºC (water bath). Acid 
chlorides, thioamides, hydrazine hydrate and hydrazinium acetate, substituted hydrazines 
were purchased from Sigma-Aldrich. C-(2,3,4,6-tetra-O-benzoyl-β-D-
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glucopyranosyl)formamide25 (1) and C-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)thioformamide32 (11) were synthesized according to published procedures. 
 
General procedure I for the acylation of C-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)formamide. 
To a solution of C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamide25 (1) in 
anhydrous CHCl3 (10 mL/mmol) the corresponding acid chloride (5.0 equiv.) and pyridine 
(5.0 equiv.) were added. The reaction mixture was stirred at rt and monitored by TLC (1:8 
EtOAc/toluene). After complete conversion of 1 the mixture was diluted with CHCl3 (30 mL) 
and extracted with NaHCO3 (2 × 10 mL) then with water (1 × 10 mL). The organic phase was 
dried over MgSO4, concentrated under diminished pressure, and the crude product was 
purified by column chromatography. 
 
General procedure II for the preparation of N-acyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)thioformamides. 
To a solution of the C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)thioformamide32 (11) in 
anhydrous CHCl3 (10 mL/mmol) the corresponding acid chloride (1.5 equiv.) and pyridine 
(1.5 equiv.) were added. The reaction mixture was stirred at rt and monitored by TLC (1:8 
EtOAc/toluene). After complete conversion of 11 the mixture was diluted with CHCl3 (30 
mL) and extracted with NaHCO3 (2 × 10 mL) then with water (1 × 10 mL). The organic phase 
was dried over MgSO4, concentrated under diminished pressure, and the crude product was 
purified by column chromatography. 
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General procedure III for the preparation of N-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosylcarbonyl) thioamides. 
C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formic acid was boiled in SOCl2 (10 
mL/mmol) for 2 hours, then the excess of SOCl2 was evaporated under reduced pressure. 
Traces of the reagents were removed by repeated co-evaporations with anhydorus toluene. 
The resulting acid chloride 1720 was dissolved in anhydrous CH3CN (15 mL/mmol), and the 
solution of the corresponding thioamide (2.0 equiv.) and pyridine (2.0 equiv.) in anhydrous 
CH3CN (15 mL/mmol) were added dropwise over 20 minutes. The reaction mixture was 
stirred at rt. After complete conversion of 17 (monitored by TLC, 1:1 EtOAc/hexane, 12 h) 
the solvent was removed and the residue was purified by column chromatography. 
 
General procedure IV for the preparation of 1,5-disubstituted-3-(2’,3’,4’,6’-tetra-O-
benzoyl-β-D-glucopyranosyl)-1,2,4-triazoles and 1,3-disubstituted-5-(2’,3’,4’,6’-tetra-O-
benzoyl-β-D-glucopyranosyl)-1,2,4-triazoles. 
To a solution of an N-acyl-thioamide 12-15, 18, or 19 in anhydrous pyridine (10 mL/mmol) 
the corresponding hydrazine (1.2 equiv.) was added, and the reaction mixture was stirred at rt 
for 2 h. After complete conversion of the starting material (monitored by TLC, 2:1 
EtOAc/hexane) the solvent was removed and the residue was purified by column 
chromatography.  
 
General procedure V for the removal of O-acyl protecting groups by the Zemplén 
protocol.  
An O-acylated compound was dissolved in dry MeOH (5 mL/ 100 mg) and 1-2 drops of a 1 
M methanolic NaOMe solution were added. The mixture was kept at rt and monitored by 
TLC (3:7 MeOH/CHCl3). When the starting material was consumed the mixture was 
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neutralised with a cation exchange resin Amberlyst 15 (H+ form) or with acetic acid, then the 
resin was filtered off and the solvent removed. The residue was purified by column 
chromatography. 
 
Synthesis and characterization of the compounds 
 
N-Acetyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamide (2)  
Prepared from compound 1 (0.25 g, 0.40 mmol) and acetyl chloride (0.14 mL, 2.00 mmol) 
according to general procedure I (reaction time: 12 h). Purified by column chromatography 
(1:4 EtOAc/hexane) to give 0.14 g (51 %) white amorphous solid. Rf = 0.27 (1:2 
EtOAc/hexane); [α]D ‒2 (c 0.58, CHCl3);  1H NMR (400 MHz, CDCl3) δ (ppm): 8.99 (1H, s, 
NH), 8.06 (2H, dd, J = 8.2, 1.1 Hz, aromatics), 7.97–7.91 (4H, m, aromatics), 7.83 (2H, dd, J 
= 8.2, 1.1 Hz, aromatics), 7.58–7.25 (12H, m, aromatics), 5.99 (1H, pseudo t, J = 9.2 Hz, H-2’ 
or H-3’ or H-4’), 5.75–5.66 (2H, m, H-2’ and/or H-3’ and/or H-4’), 4.72 (1H, dd, J = 12.5, 2.6 
Hz, H-6’a ), 4.55 (1H, dd, J = 12.5, 5.3 Hz, H-6’b), 4.37 (1H, d, J = 9.5 Hz, H-1’), 4.27 (1H, 
ddd, J = 9.6, 5.2, 2.7 Hz, H-5’), 2.37 (3H, s, CH3); 13C NMR (100 MHz, CDCl3) δ (ppm): 
171.9, 166.4, 166.0, 165.7, 165.4, 165.2 (C=O), 133.7–128.5 (aromatics), 76.8, 76.5, 73.2, 
69.8, 68.9 (C-1’–C-5’), 62.8 (C-6’), 25.4 (CH3). ESI-MS positive mode (m/z): [M+Na]+, 
found 688.18; C37H31NNaO11 requires 688.180. Anal. Calcd for C37H31NO11: C, 66.76; H, 
4.69; N, 2.10. Found: C, 66.88; H, 4.75; N, 2.08. 
 
N-Benzoyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamide (3)  
Prepared from compound 1 (0.25 g, 0.40 mmol) and benzoyl chloride (0.23 mL, 2.00 mmol) 
according to general procedure I (reaction time: 3 d). Purified by column chromatography 
(1:3 EtOAc/hexane) to give 0.08 g (26 %) white amorphous solid. Rf = 0.38 (1:1 
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EtOAc/hexane); [α]D ‒1 (c 0.51, CHCl3); 1H NMR (400 MHz, CDCl3) δ (ppm): 9.47 (1H, s, 
NH), 8.01 (2H, dd, J = 8.2, 1.1 Hz, aromatics), 7.96–7.93 (3H, m, aromatics), 7.83 (3H, d, J = 
8.1 Hz, aromatics), 7.56–7.26 (17H, m, aromatics), 6.00 (1H, pseudo t, J = 9.2 Hz, H-2’ or H-
3’ or H-4’), 5.84 (1H, pseudo t, J = 9.4 Hz, H-2’ or H-3’ or H-4’), 5.76 (1H, pseudo t, J = 9.5 
Hz, H-2’ or H-3’ or H-4’), 4.78 (1H, dd, J = 12.5, 2.5 Hz, H-6’a ), 4.69 (1H, d, J = 9.5 Hz, H-
1’), 4.58 (1H, dd, J = 12.5, 5.3 Hz, H-6’b), 4.32 (1H, ddd, J = 10.0, 5.3, 2.5 Hz, H-5’); 13C 
NMR (100 MHz, CDCl3) δ (ppm): 166.4, 165.8, 165.5, 165.3, 165.3, 164.7 (C=O), 133.8–
128.0 (aromatics), 76.9, 76.7, 73.6, 69.5, 68.9 (C-1’–C-5’), 62.5 (C-6’). ESI-MS positive 
mode (m/z): calcd for C42H33NNaO11 ([M+Na]
+): 750.195. Found: 750.19. Anal. Calcd for 
C42H33NO11: C, 69.32; H, 4.57; N, 1.92. Found: C, 69.46; H, 4.47; N, 1.90. 
 
N-(1-Naphthoyl)-C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamide (4)  
Prepared from compound 1 (0.20 g, 0.32 mmol) and naphthoyl chloride (0.24 mL, 1.6 mmol) 
according to general procedure I (reaction time: 1 d). Purified by column chromatography 
(1:1:3 EtOAc/toluene/hexane) to give 0.04 g (16 %) white amorphous solid. Rf = 0.42 (1:3:1 
EtOAc/toluene/hexane); [α]D ‒4 (c 0.53, CHCl3); 1H NMR (400 MHz, CDCl3) δ (ppm): 9.29 
(1H, s, NH), 8.33 (1H, d, J = 7.3 Hz, aromatics), 7.98–7.79 (9H, m, aromatics), 7.72 (1H, d, J 
= 6.8 Hz, aromatics), 7.57–7.20 (16H, m, aromatics), 5.98 (1H, pseudo t, J = 9.2 Hz, H-2’ or 
H-3’ or H-4’), 5.84 (1H, pseudo t, J = 9.4 Hz, H-2’ or H-3’ or H-4’), 5.71 (1H, pseudo t, J = 
9.5 Hz, H-2’ or H-3’ or H-4’), 4.67 (2H, m, H-6’and H-1’), 4.52 (1H, dd, J = 12.4, 5.4 Hz, H-
6’b), 4.28 (1H, ddd, J = 10.1, 5.5, 2.6 Hz, H-5’); 13C NMR (90 MHz, CDCl3) δ (ppm): 166.8, 
166.3, 165.8, 165.5, 165.3, 165.3 (C=O), 133.8–124.6 (aromatics), 76.9, 76.6, 73.6, 69.5, 68.9 
(C-1’–C-5’), 62.6 (C-6’). ESI-MS positive mode (m/z): calcd for C46H35NNaO11 ([M+Na]+): 
800.211. Found: 800.21. Anal. Calcd for C46H35NO11: C, 71.04; H, 4.54; N, 1.80. Found: C, 
71.28; H, 4.60; N, 1.82. 
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N,N-Diacetyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamide (5)  
Prepared from compound 1 (0.25 g, 0.40 mmol) and acetyl chloride (0.14 mL, 2.00 mmol) 
according to general procedure I (reaction time: 12 h). Purified by column chromatography 
(1:4 EtOAc/hexane) to give 0.10 g (34 %) white amorphous solid. Rf = 0.33 (1:2 
EtOAc/hexane); [α]D +80 (c 0.51, CHCl3); 1H NMR (400 MHz, CDCl3) δ (ppm): 8.09 (2H, d, 
J = 8.3 Hz, aromatics), 7.96–7.90 (4H, m, aromatics), 7.84 (2H, d, J = 8.4 Hz, aromatics), 
7.60–7.25 (12H, m, aromatics), 6.00 (1H, pseudo t, J = 9.5 Hz, H-2’ or H-3’ or H-4’), 5.92 
(1H, pseudo t, J = 9.3 Hz, H-2’ or H-3’ or H-4’), 5.69 (1H, pseudo t, J = 9.6 Hz, H-2’ or H-3’ 
or H-4’), 4.84 (1H, d, J = 9.6 Hz, H-1’), 4.67 (1H, dd, J = 12.6, 2.4 Hz, H-6’a ), 4.42 (1H, dd, 
J = 12.6, 5.1 Hz, H-6’b), 4.16 (1H, ddd, J = 9.6, 5.1, 2.4 Hz, H-5’), 2.33 (6H, s, 2 × CH3); 13C 
NMR (90 MHz, CDCl3) δ (ppm): 174.2, 174.2, 170.5, 166.1, 165.9, 165.2, 165.1 (C=O), 
133.7–128.4 (aromatics), 77.1, 76.4, 74.2, 69.2, 68.7 (C-1’–C-5’), 62.7 (C-6’), 26.3 (2 × 
CH3). ESI-MS positive mode (m/z): calcd for C39H33NNaO12 ([M+Na]
+): 730.190. Found: 
730.19. Anal. Calcd for C39H33NO12: C, 66.19; H, 4.70; N, 1.98. Found: C, 66.32; H, 4.76; N, 
1.93. 
 
N,N-Dibenzoyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamide (6)  
Prepared from compound 1 (0.25 g, 0.40 mmol) and benzoyl chloride (0.23 mL, 2.00 mmol) 
according to general procedure I (reaction time: 3 d). Purified by column chromatography 
(1:3 EtOAc/hexane) to give 0.01 g (26 %) white amorphous solid. Rf = 0.48 (1:1 
EtOAc/hexane); [α]D +88 (c 0.50, CHCl3); 1H NMR (400 MHz, CDCl3) δ (ppm): 8.12 (1H, d, 
J = 7.4 Hz, aromatics), 7.92–7.84 (7H, m, aromatics), 7.75 (3H, d, J = 7.5 Hz, aromatics), 
7.48–7.24 (19H, m, aromatics), 6.13 (1H, pseudo t, J = 9.6 Hz, H-2’ or H-3’ or H-4’), 5.94 
(1H, pseudo t, J = 9.4 Hz, H-2’ or H-3’ or H-4’), 5.76 (1H, pseudo t, J = 9.5 Hz, H-2’ or H-3’ 
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or H-4’), 5.11 (1H, d, J = 9.9 Hz, H-1’), 4.35 (1H, dd, J = 12.5, 2.3 Hz, H-6’b), 4.26–4.19 
(2H, m, H-6’a and H-5’); 13C NMR (100 MHz, CDCl3) δ (ppm): 172.1, 1 72.1, 171.6, 166.0, 
165.9, 165.2, 164.9 (C=O), 133.9–128.4 (aromatics), 77.1, 76.3, 74.5, 69.4, 68.6 (C-1’–C-5’), 
62.6 (C-6’). ESI-MS positive mode (m/z): calcd for C49H37NNaO12 ([M+Na]+): 854.221. 
Found: 854.22. Anal. Calcd for C49H37NO12: C, 70.75; H, 4.48; N, 1.68. Found: C, 70.99; H, 
4.53; N, 1.61. 
 
N,N-Bis-(1-naphthoyl)-C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamide (7)  
Prepared from compound 1 (0.20 g, 0.32 mmol) and naphthoyl chloride (0.24 mL, 1.6 mmol) 
according to general procedure I (reaction time: 1 d). Purified by column chromatography 
(1:1:3 Toluene/EtOAc/hexane) to give 0.05 g (15 %) white amorphous solid. Rf = 0.28 (3:1:1 
Toluene/EtOAc/hexane); [α]D +44 (c 0.61, CHCl3); 1H NMR (400 MHz, CDCl3) δ (ppm): 
8.14 (2H, d, J = 8.2 Hz, aromatics), 7.98–7.85 (8H, m, aromatics), 7.65 (2H, d, J = 7.7 Hz, 
aromatics), 7.56–7.22 (18H, m, aromatics), 7.13 (2H, t, J = 7.7 Hz, aromatics), 6.97 (2H, t, J 
= 7.7 Hz, aromatics), 6.28 (1H, pseudo t, J = 9.6 Hz, H-2’ or H-3’ or H-4’), 5.99 (1H, pseudo 
t, J = 9.5 Hz, H-2’ or H-3’ or H-4’), 5.76 (1H, pseudo t, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 
5.19 (1H, d, J = 9.8 Hz, H-1’), 4.50 (1H, dd, J = 12.5, 2.0 Hz, H-6’a ), 4.35 (1H, dd, J = 12.5, 
5.2 Hz, H-6’b), 4.25 (1H, ddd, J = 10.0, 5.3, 2.0 Hz, H-5’); 13C NMR (100 MHz, CDCl3) δ 
(ppm): 171.7, 171.7, 171.7, 166.0, 166.0, 165.2, 165.0, (C=O), 133.7–124.2 (aromatics), 77.1, 
77.0, 74.5, 69.7, 68.5 (C-1’–C-5’), 62.8 (C-6’). ESI-MS positive mode (m/z): calcd for 
C57H41NNaO12 ([M+Na]
+): 954.253. Found: 954.25. Anal. Calcd for C57H41NO12: C, 73.46; 
H, 4.43; N, 1.50. Found: C, 73.60; H, 4.59; N, 1.45. 
 
Acetone N2-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosylcarbonyl)hydrazone (10) 
To a solution of imide 2 (0.10 g, 0.15 mmol) in pyridine was added hydrazine hydrate (9 µL, 
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1.2 equiv., 0.18 mmol) and the reaction mixture was stirred at room temperature. After 
disappearance of the starting material (3h, TLC, 1:1 Acetone/hexane) the solvent was 
removed and the purification by column chromatography (1:3 Acetone/hexane) yielded 0.04 g 
(39 %) yellow syrup. Rf = 0.26 (1:1 Acetone/hexane); [α]D ‒24 (c 0.29, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ (ppm): 8.07 (2H, dd, J = 8.2, 1.1 Hz, aromatics), 7.97–7.94 (4H, m, 
aromatics), 7.83 (2H, dd, J = 8.2, 1.1 Hz, aromatics), 7.62–7.26 (12H, m, aromatics), 5.96 
(1H, pseudo t, J = 9.2 Hz, H-2’ or H-3’ or H-4’), 5.74 (1H, pseudo t, J = 9.5 Hz, H-2’ or H-3’ 
or H-4’), 5.71 (1H, pseudo t, J = 9.5 Hz, H-2’ or H-3’ or H-4’), 4.83 (1H, dd, J = 12.5, 2.4 Hz, 
H-6’a ), 4.53 (1H, dd, J = 12.5, 4.9 Hz, H-6’b), 4.44 (1H, d, J = 9.5 Hz, H-1’), 4.21 (1H, ddd, 
J = 9.9, 4.9, 2.4 Hz, H-5’), 2.05 (3H, s, CH3), 1.85 (3H, s, CH3); 13C NMR (100 MHz, CDCl3) 
δ (ppm): 166.3, 165.8, 165.5, 165.3, 162.4 (C=O), 157.3 (C=N), 133.8–128.3 (aromatics), 
76.7, 76.3, 73.5, 70.2, 68.8 (C-1’–C-5’), 62.1 (C-6’), 25.6, 16.6 (2 × CH3). ESI-MS positive 
mode (m/z): calcd for C38H34N2NaO10 ([M+Na]
+): 701.211. Found: 701.21. Anal. Calcd for 
C38H34N2O10: C, 67.25; H, 5.05; N, 4.13. Found: C, 67.54; H, 5.18; N, 4.05. 
 
N-Acetyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)thioformamide (12)  
Prepared from compound 11 (1.00 g, 1.56 mmol) and acetyl chloride (168 µL, 2.35 mmol) 
according to general procedure II (reaction time: 1 h). Purified by column chromatography 
(1:3 EtOAc/hexane) to give 0.96 g (91 %) red foam. Rf = 0.50 (1:1 EtOAc/hexane); [α]D = 
+20 (c 0.53, CHCl3);
 1H NMR (360 MHz, CDCl3) δ (ppm): 9.97 (1H, s, NH), 8.07 (2H, dd, J 
= 8.2, 1.1 Hz, aromatics), 7.94–7.90 (4H, m, aromatics), 7.81 (2H, dd, J = 8.2, 1.1 Hz, 
aromatics), 7.59–7.24 (12H, m, aromatics), 5.99 (1H, pseudo t, J = 9.3 Hz, H-2’ or H-3’ or H-
4’), 5.76 (1H, pseudo t, J = 9.6 Hz, H-2’ or H-3’ or H-4’), 5.68 (1H, pseudo t, J = 9.3 Hz, H-
2’ or H-3’ or H-4’), 4.88 (1H, d, J = 9.0 Hz, H-1’), 4.72 (1H, dd, J = 12.4, 2.6 Hz, H-6’a), 
4.57 (1H, dd, J = 12.5, 5.3 Hz, H-6’b), 4.30 (1H, ddd, J = 9.8, 5.2, 2.7 Hz, H-5’), 2.42 (3H, s, 
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CH3); 
13C NMR (90 MHz, CDCl3) δ (ppm): 197.3 (C=S), 170.5, 166.4, 165.7, 165.3, 165.2 
(C=O), 133.6–128.2 (aromatics), 84.9, 76.2, 73.4, 71.2, 69.0 (C-1’–C-5’), 62.9 (C-6’), 26.3 
(CH3). ESI-MS negative mode (m/z): calcd for C37H30NO10S ([M-H]
-): 680.159. Found: 
680.08. Anal. Calcd for C37H31NO10S: C, 65.19; H, 4.58; N, 2.05; S, 4.70. Found: C, 65.33; 
H, 4.77; N, 2.09; S, 4.81. 
 
N-Acetoxyacetyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)thioformamide (13)  
Prepared from compound 11 (1.20 g, 1.87 mmol) and acetoxyacetyl chloride (303 µL, 2.81 
mmol) according to general procedure II (reaction time: 6 h). Purified by column 
chromatography (1:3 EtOAc/hexane) to give 1.18 g (85 %) red foam. Rf = 0.25 (1:2 
EtOAc/hexane); [α]D = +60 (c 0.45, CHCl3); 1H NMR (400 MHz, CDCl3) δ (ppm): 10.22 (1H, 
s, NH), 8.06 (2H, d, J = 7.2 Hz, aromatics), 7.93–7.90 (4H, m, aromatics), 7.81 (2H, d, J = 7.2 
Hz, aromatics), 7.60–7.25 (12H, m, aromatics), 5.99 (1H, pseudo t, J = 9.3 Hz, H-2’ or H-3’ 
or H-4’), 5.74 (1H, pseudo t, J = 9.6 Hz, H-2’ or H-3’ or H-4’), 5.69 (1H, pseudo t, J = 9.3 
Hz, H-2’ or H-3’ or H-4’), 5.04 (1H, d, J = 16.8 Hz, CH2 ), 4.89 (1H, d, J = 9.3 Hz, H-1’), 
4.84 (1H, d, J = 16.8 Hz, CH2), 4.67 (1H, dd, J = 12.6, 2.6 Hz, H-6’a), 4.58 (1H, dd, J = 12.5, 
5.6 Hz, H-6’b), 4.30 (1H, ddd, J = 9.6, 5.5, 2.5 Hz, H-5’), 2.15 (3H, s, CH3); 13C NMR (100 
MHz, CDCl3) δ (ppm): 197.0 (C=S), 169.9, 167.3, 166.4, 165.7, 165.3, 165.2 (C=O), 133.8–
128.5 (aromatics), 84.6, 76.4, 73.4, 71.2, 69.0 (C-1’–C-5’), 64.4 (CH2), 63.0 (C-6’) 20.6 
(CH3). ESI-MS negative mode (m/z): calcd for C39H32NO12S ([M-H]
-): 738.165. Found: 
738.18. Anal. Calcd for C39H33NO12S: C, 63.32; H, 4.50; N, 1.89; S, 4.33. Found: C, 63.67; 
H, 4.74; N, 1.87; S, 4.41. 
 
N-Pivaloyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)thioformamide (14)  
Prepared from compound 11 (1.10 g, 1.72 mmol) and pivaloyl chloride (317 µL, 2.58 mmol) 
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according to general procedure II (reaction time: 1 h). Purified by column chromatography 
(1:4 Acetone/hexane) to give 1.11 g (90 %) red foam. Rf = 0.50 (1:2 Acetone/hexane); [α]D = 
+42 (c 0.53, CHCl3);
 1H NMR (400 MHz, CDCl3) δ (ppm): 10.10 (1H, s, NH), 8.06 (2H, d, J 
= 8.2 Hz, aromatics), 7.95–7.88 (4H, m, aromatics), 7.82 (2H, d, J = 8.2 Hz, aromatics), 7.62–
7.24 (12H, m, aromatics), 5.99 (1H, pseudo t, J = 9.3 Hz, H-2’ or H-3’ or H-4’), 5.80 (1H, 
pseudo t, J = 9.6 Hz, H-2’ or H-3’ or H-4’), 5.71 (1H, pseudo t, J = 9.4 Hz, H-2’ or H-3’ or H-
4’), 5.04 (1H, d, J = 9.0 Hz, H-1’), 4.75 (1H, dd, J = 12.5, 2.4 Hz, H-6’a), 4.54 (1H, dd, J = 
12.5, 4.7 Hz, H-6’b), 4.31 (1H, ddd, J = 9.8, 4.5, 2.5 Hz, H-5’), 1.20 (9H, s, C(CH3)3; 13C 
NMR (100 MHz, CDCl3) δ (ppm): 196.8 (C=S), 175.1, 166.1, 165.7, 165.2, 165.1 (C=O), 
133.8–128.4 (aromatics), 84.2, 76.2, 73.7, 71.3, 68.9 (C-1’–C-5’), 62.4 (C-6’), 40.9 
(C(CH3)3), 26.9 (C(CH3)3). ESI-MS positive mode (m/z): calcd for C40H38NO10S ([M+H]
+): 
724.222. Found: 724.33. Anal. Calcd for C40H37NO10S: C, 66.38; H, 5.15; N, 1.94; S, 4.43. 
Found: C, 66.52; H, 5.20; N, 1.90; S, 4.53. 
 
N-Phenylacetyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)thioformamide (15)  
Prepared from compound 11 (1.10 g, 1.72 mmol) and 2-phenylacetyl chloride (341 µL, 2.58 
mmol) according to general procedure II (reaction time: 1d). Purified by column 
chromatography (1:5 EtOAc/hexane) to give 0.90 g (69 %) red foam. Rf = 0.52 (1:1 
EtOAc/hexane); [α]D = +15 (c 0.51, CHCl3); 1H NMR (360 MHz, CDCl3) δ (ppm): 9.88 (1H, 
s, NH), 8.04 (2H, d, J = 7.9 Hz, aromatics), 7.92–7.89 (4H, m, aromatics), 7.80 (2H, d, J = 7.9 
Hz, aromatics), 7.59–7.26 (17H, m, aromatics), 5.92 (1H, pseudo t, J = 9.3 Hz, H-2’ or H-3’ 
or H-4’), 5.57 (2H, pseudo t, J = 9.6 Hz, H-2’ and/or H-3’ and/or H-4’), 4.85 (1H, d, J = 8.6 
Hz, H-1’), 4.55 (1H, dd, J = 12.3, 2.5 Hz, H-6’a), 4.37 (1H, dd, J = 12.4, 5.8 Hz, H-6’b), 4.22 
(1H, ddd, J = 9.1, 5.6, 2.5 Hz, H-5’), 3.90 (2H, s, PhCH2); 13C NMR (90 MHz, CDCl3) δ 
(ppm): 196.6 (C=S), 169.3, 166.4, 165.7, 165.3, 165.2 (C=O), 133.8–128.2 (aromatics), 84.4, 
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76.2, 73.5, 71.2, 69.2 (C-1’–C-5’), 63.3 (C-6’) 45.3 (PhCH2). ESI-MS positive mode (m/z): 
calcd for C43H36NO10S ([M+H]
+): 758.206. Found: 758.25. Anal. Calcd for C43H35NO10S: C, 
68.15; H, 4.66; N, 1.85; S, 4.23. Found: C, 68.33; H, 4.80; N, 1.90; S, 4.39. 
 
N-(2,3,4,6-Tetra-O-benzoyl-β-D-glucopyranosylcarbonyl) thioacetamide (18)  
Prepared from compound 17 (0.21 g, 0.32 mmol) and thioacetamide (0.02 g, 0.64 mmol) 
according to general procedure III. Purified by column chromatography (1:3 EtOAc/hexane) 
to give 0.12 g (58 %) yellow amorphous solid. Rf = 0.46 (1:2 EtOAc/hexane); [α]D ‒146 (c 
0.38, CHCl3);
 1H NMR (360 MHz, CDCl3) δ (ppm): 10.17 (1H, s, NH), 8.09–7.25 (20H, m, 
aromatics), 6.00 (1H, pseudo t, J = 9.3 Hz, H-2’ or H-3’ or H-4’), 5.72 (1H, pseudo t, J = 9.3 
Hz, H-2’ or H-3’ or H-4’), 5.70 (1H, pseudo t, J = 9.3 Hz, H-2’ or H-3’ or H-4’), 4.76 (1H, 
dd, J = 12.5, 2.7 Hz, H-6’a), 4.57 (1H, dd, J = 12.5, 5.1 Hz, H-6’b), 4.37 (1H, d, J = 9.3 Hz, 
H-1’), 4.28 (1H, ddd, J = 9.8, 5.1, 2.7 Hz, H-5’), 2.88 (3H, s, CH3); 13C NMR (90 MHz, 
CDCl3) δ (ppm): 210.6 (C=S), 166.3, 165.7, 165.4, 165.2, 163.4 (C=O), 133.8–128.5 
(aromatics), 76.6, 76.6, 73.0, 69.8, 68.8 (C-1’–C-5’), 62.5 (C-6’), 35.0 (CH3);. ESI-MS 
positive mode (m/z): calcd for C37H31NNaO10S ([M+Na]
+): 704.157. Found: 704.15. Anal. 
Calcd for C37H31NO10S: C, 65.19; H, 4.58; N, 2.05; S, 4.70. Found: C, 65.41; H, 4.60; N, 
2.03; S, 4.78. 
 
N-(2,3,4,6-Tetra-O-benzoyl-β-D-glucopyranosylcarbonyl) thiobenzamide (19)  
Prepared from compound 17 (0.21 g, 0.32 mmol) and thiobenzamide (0.04 g, 0.64 mmol) 
according to general procedure III. Purified by column chromatography (1:3 EtOAc/hexane) 
to give 0.17 g (71 %) red solid. Mp: 124–127 °C; Rf = 0.54 (1:2 EtOAc/hexane); [α]D ‒204 (c 
0.36, CHCl3);
 1H NMR (360 MHz, CDCl3) δ (ppm): 10.38 (1H, s, NH), 8.04–7.23 (25H, m, 
aromatics), 6.00 (1H, pseudo t, J = 9.3 Hz, H-2’ or H-3’ or H-4’), 5.84 (1H, pseudo t, J = 9.3 
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Hz, H-2’ or H-3’ or H-4’), 5.78 (1H, pseudo t, J = 9.3 Hz, H-2’ or H-3’ or H-4’), 4.78 (1H, 
dd, J = 12.3, 1.8 Hz, H-6’a), 4.59 (1H, dd, J = 12.3, 5.0 Hz, H-6’b), 4.51 (1H, d, J = 9.3 Hz, 
H-1’), 4.31 (1H, ddd, J = 9.6, 5.0, 1.8 Hz, H-5’); 13C NMR (90 MHz, CDCl3) δ (ppm): 202.2 
(C=S), 166.3, 165.7, 165.3, 165.2, 163.5 (C=O), 141.9–127.5 (aromatics), 76.7, 76.6, 73.2, 
69.6, 68.7 (C-1’–C-5’), 62.4 (C-6’). ESI-MS positive mode (m/z): calcd for C42H33NNaO10S 
([M+Na]+): 766.172. Found: 766.17. Anal. Calcd for C42H33NO10S: C, 67.82; H, 4.47; N, 1.88 
S, 4.31. Found: C, 67.98; H, 4.56; N, 1.90; S, 4.30. 
 
3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-5-methyl-1,2,4-triazole (20) 
Prepared from compound 12 (0.10 g, 0.15 mmol) and hydrazinium acetate (16 mg, 0.18 
mmol) according to general procedure IV. Purification by column chromatography (3:2 
EtOAc/hexane) yielded 0.06 g (55 %) pale yellow amorphous solid.  
Prepared from compound 18 (0.12 g, 0.18 mmol) and hydrazinium acetate (19 mg, 0.21 
mmol) according to general procedure IV. Purification by column chromatography (3:2 
EtOAc/hexane) yielded 0.07 g (57 %) pale yellow amorphous solid.  
The compound characterization data are identical with those reported 20. 
 
3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-5-methyl-1-phenyl-1,2,4-triazole (21) 
Prepared from compound 12 (0.35 g, 0.51 mmol) and phenylhydrazine (61 µL, 0.62 mmol) 
according to general procedure IV. Purified by column chromatography (1:2 Acetone/hexane) 
to give 0.27 g (71 %) pale yellow amorphous solid. Rf = 0.42 (1:1 Acetone/hexane); [α]D = 
+12 (c 0.50, CHCl3);
 1H NMR (400 MHz, CDCl3) δ (ppm): 8.00 (2H, dd, J = 8.3, 1.2 Hz, 
aromatics), 7.92 (2H, dd, J = 8.3, 1.1 Hz, aromatics), 7.88–7.85 (4H, m, aromatics), 7.51–7.21 
(17H, m, aromatics), 6.17 (1H, pseudo t, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 6.07 (1H, pseudo 
t, J = 9.5 Hz, H-2’ or H-3’ or H-4’), 5.88 (1H, pseudo t, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 
24 
 
5.08 (1H, d, J = 9.8 Hz, H-1’), 4.66 (1H, dd, J = 12.3, 3.1 Hz, H-6’a), 4.59 (1H, dd, J = 12.3, 
5.0 Hz, H-6’b), 4.38 (1H, ddd, J = 9.7, 4.9, 3.2 Hz, H-5’), 2.46 (3H, s, CH3); 13C NMR (100 
MHz, CDCl3) δ (ppm): 166.3, 165.9, 165.2, 164.7 (C=O), 158.5, 153.4 (triazole C-3, C-5), 
137.1 (q, Ph), 133.4–124.5 (aromatics), 76.8, 74.7, 74.6, 71.5, 69.8 (C-1’–C-5’), 63.7 (C-6’), 
13.3 (CH3). ESI-MS positive mode (m/z): calcd for C43H36N3O9 ([M+H]
+): 738.245. Found: 
738.25. Anal. Calcd for C43H35N3O9: C, 70.01; H, 4.78; N, 5.70. Found: C, 70.27; H, 4.90; N, 
5.65. 
 
3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-1-(2-hydroxyethyl)-5-methyl-1,2,4-
triazole (22) 
Prepared from compound 12 (0.33 g, 0.49 mmol) and 2-hydroxyethylhydrazine (40 µL, 0.58 
mmol) according to general procedure IV. Purified by column chromatography (1:2 
Acetone/hexane) to give 0.24 g (70 %) pale yellow amorphous solid. Rf = 0.15 (4:1 
EtOAc/hexane); [α]D = +21 (c 0.55, CHCl3); 1H NMR (400 MHz, CDCl3) δ (ppm): 8.00 (2H, 
dd, J = 8.2, 1.0 Hz, aromatics), 7.92 (2H, dd, J = 8.2, 1.1 Hz, aromatics), 7.82–7.85 (4H, m, 
aromatics), 7.51–7.23 (12H, m, aromatics), 6.09–5.99 (2H, m, H-2’ and/or H-3’ and/or H-4’), 
5.85 (1H, pseudo t, J = 9.5 Hz, H-2’ or H-3’ or H-4’), 4.96 (1H, d, J = 9.3 Hz, H-1’), 4.65 
(1H, dd, J = 12.3 3.0 Hz, H-6’a), 4.57 (1H, dd, J = 12.3, 5.1 Hz, H-6’b), 4.35 (1H, ddd, J = 
9.6, 5.0, 3.2 Hz, H-5’), 4.00 (2H, t, J = 4.7 Hz, CH2), 3.95–3.90 (1H, m, CH2), 3.75–3.71 (1H, 
m, CH2), 3.13 (1H, br s, OH), 2.34 (3H, s, CH3); 
13C NMR (100 MHz, CDCl3) δ (ppm): 
166.2, 165.9, 165.3, 165.2 (C=O), 158.0, 154.1 (triazole C-3, C-5), 133.4–128.3 (aromatics), 
76.7, 74.7, 74.3, 72.1, 69.7 (C-1’–C-5’), 63.6 (C-6’), 60.6, 50.5 (2 × CH2), 11.9 (CH3). ESI-
MS positive mode (m/z): calcd for C39H36N3O10 ([M+H]
+): 706.240. Found: 706.28. Anal. 
Calcd for C39H35N3O10: C, 66.38; H, 5.00; N, 5.95. Found: C, 66.40; H, 5.09; N, 6.03. 
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3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-5-methyl-1-tosyl-1,2,4-triazole (23)  
Prepared from compound 12 (0.10 g, 0.15 mmol) and tosylhydrazine (34 mg, 0.18 mmol) 
according to general procedure IV. Purification by column chromatography (1:2 
EtOAc/hexane) yielded 0.08 g (63%) pale yellow amorphous solid. The compound 
characterization data are identical with those reported.20 
 
5-(Acetoxymethyl)-3-(2′,3′,4′,6′-tetra-O-benzoyl-β-D-glucopyranosyl)-1,2,4-triazole (24) 
Prepared from compound 13 (0.10 g, 0.14 mmol) hydrazinium acetate (15 mg, 0.16 mmol) 
according to general procedure IV. Purification by column chromatography (1:2 
EtOAc/hexane) yielded 0.09 g (92 %) pale yellow amorphous solid. The compound 
characterization data are identical with those reported.20 
 
5-(Acetoxymethyl)-3-(2′,3′,4′,6′-tetra-O-benzoyl-β-D-glucopyranosyl)-1-phenyl-1,2,4-
triazole (25) 
Prepared from compound 13 (0.30 g, 0.41 mmol) and phenylhydrazine (48 µL, 0.49 mmol) 
according to general procedure IV. Purified by column chromatography (1:2 EtOAc/hexane) 
to give 0.22 g (70 %) pale yellow amorphous solid. Rf = 0.28 (1:1 EtOAc/hexane); [α]D = +4 
(c 0.48, CHCl3);
 1H NMR (400 MHz, CDCl3) δ (ppm): 8.01 (2H, dd, J = 8.2, 1.1 Hz, 
aromatics), 7.92 (2H, dd, J = 8.2, 1.0, aromatics), 7.88–7.84 (4H, m, aromatics), 7.51–7.23 
(17H, m, aromatics), 6.20 (1H, pseudo t, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 6.09 (1H, pseudo 
t, J = 9.5 Hz, H-2’ or H-3’ or H-4’), 5.90 (1H, pseudo t, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 
5.15 (1H, d, J = 9.8 Hz, H-1’), 5.12 (2H, s, CH2), 4.68 (1H, dd,  J = 12.3, 3.0 Hz, H-6’a), 4.59 
(1H, dd, J = 12.3, 5.0 Hz, H-6’b), 4.40 (1H, ddd, J = 9.7, 4.8, 3.1 Hz, H-5’), 1.96 (3H, s, 
CH3); 
13C NMR (100 MHz, CDCl3) δ (ppm): 169.8, 166.2, 165.9, 165.2, 164.6 (C=O), 159.2, 
151.2 (triazole C-3, C-5), 136.5 (q, Ph), 133.4–124.6 (aromatics), 76.8, 74.5, 74.5, 71.5, 69.7 
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(C-1’–C-5’), 63.5 (C-6’), 56.3 (CH2), 20.3 (CH3). ESI-MS positive mode (m/z): calcd for 
C45H38N3O11 ([M+H]
+): 796.251. Found: 796.25. Anal. Calcd for C45H37N3O11: C, 67.92; H, 
4.69; N, 5.28. Found: C, 68.11; H, 4.82; N, 5.22. 
 
3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-1-(2-hydroxyethyl)-5-
(hydroxymethyl)-1,2,4-triazole (26) 
Prepared from compound 13 (0.30 g, 0.41 mmol) and 2-hydroxyethylhydrazine (33 µL, 0.49 
mmol) according to general procedure IV. Purified by column chromatography (1:2 
EtOAc/hexane) to give 0.19 g (65 %) pale yellow amorphous solid. Rf = 0.45 (2:1 
Acetone/hexane); [α]D = +6 (c 0.47, CHCl3); 1H NMR (400 MHz, CDCl3) δ (ppm): 7.98 (2H, 
dd, J = 8.2, 1.2 Hz, aromatics), 7.91 (2H, dd, J = 8.2, 1.2, aromatics), 7.84–7.79 (4H, m, 
aromatics), 7.51–7.23 (12H , m, aromatics), 6.05 (1H, pseudo t, J = 9.5 Hz, H-2’ or H-3’ or 
H-4’), 5.96 (1H, pseudo t, J = 9.6 Hz, H-2’ or H-3’ or H-4’), 5.85 (1H, pseudo t, J = 9.6 Hz, 
H-2’ or H-3’ or H-4’), 4.98 (1H, d, J = 9.6 Hz, H-1’), 4.67–4.62 (1H, m, H-6’a), 4.62 (2H, s, 
CH2), 4.53 (1H, dd, J = 12.3, 5.0 Hz, H-6’b), 4.34 (1H, ddd, J = 9.7, 4.8, 3.1 Hz, H-5’), 4.13 
(2H, t, J = 4.6 Hz, CH2), 3.82–3.77 (1H, m, CH2), 3.71–3.65 (1H, m, CH2); 13C NMR (100 
MHz, CDCl3) δ (ppm): 166.3, 165.9, 165.3, 165.3 (C=O), 158.0, 156.5 (triazole C-3, C-5), 
133.5–128.3 (aromatics), 76.7, 74.4, 74.3, 71.9, 69.7 (C-1’–C-5’), 63.5 (C-6’), 60.6, 55.0, 
51.1 (3 × CH2). ESI-MS negative mode (m/z): calcd for C41H38N3O13 ([M+OAc]-): 780.240. 
Found: 780.27. Anal. Calcd for C39H35N3O11: C, 64.90; H, 4.89; N, 5.82. Found: C, 65.22; H, 
4.99; N, 5.93. 
 
3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-5-(tert-butyl)-1,2,4-triazole (27) 
Prepared from compound 14 (0.10 g, 0.14 mmol) hydrazinium acetate (15 mg, 0.17 mmol) 
according to general procedure IV. Purification by column chromatography (1:2 
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EtOAc/hexane) yielded 0.08g (79 %) pale yellow amorphous solid. The compound 
characterization data are identical with those reported.20 
 
3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-5-(tert-butyl)-1-phenyl-1,2,4-triazole 
(28) 
Prepared from compound 14 (0.30 g, 0.41 mmol) and phenylhydrazine (48 µL, 0.49 mmol) 
according to general procedure IV. Purified by column chromatography (1:4 EtOAc/hexane) 
to give 0.21 g (66 %) pale yellow amorphous solid. Rf = 0.55 (1:1 EtOAc/hexane); [α]D = +9 
(c 0.49, CHCl3);
 1H NMR (400 MHz, CDCl3) δ (ppm): 8.01 (2H, dd, J = 8.2, 1.2 Hz, 
aromatics), 7.94–7.85 (6H, m, aromatics), 7.51–7.25 (15H , m, aromatics), 7.15–7.13 (2H, m, 
aromatics), 6.13 (1H, pseudo t, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 6.05 (1H, pseudo t, J = 9.5 
Hz, H-2’ or H-3’ or H-4’), 5.89 (1H, pseudo t, J = 9.6 Hz, H-2’ or H-3’ or H-4’), 5.05 (1H, d, 
J = 9.7 Hz, H-1’), 4.66 (1H, dd, J = 12.3, 3.1 Hz,H-6’a), 4.59 (1H, dd, J = 12.3, 5.0 Hz, H-
6’b), 4.36 (1H, ddd, J = 9.6, 4.7, 3.3 Hz, H-5’), 1.09 (9H, s, C(CH3)3); 13C NMR (100 MHz, 
CDCl3) δ (ppm): 166.3, 165.9, 165.3, 164.7 (C=O), 164.1, 157.1 (triazole C-3, C-5), 139.5 (q, 
Ph), 133.4–127.9 (aromatics), 77.0, 74.9, 74.5, 72.1, 69.9 (C-1’–C-5’), 63.7 (C-6’), 33.5 
(C(CH3)3), 29.7(C(CH3)3). ESI-MS positive mode (m/z): calcd for C46H42N3O9 ([M+H]
+): 
780.292. Found: 780.30. Anal. Calcd for C46H41N3O9: C, 70.85; H, 5.30; N, 5.39. Found: C, 
70.91; H, 5.42; N, 5.34. 
 
3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-5-(tert-butyl)-1-(2-hydroxyethyl)-
1,2,4-triazole (29) 
Prepared from compound 14 (0.30 g, 0.41 mmol) and 2-hydroxyethylhydrazine (33 µL, 0.49 
mmol) according to general procedure IV. Purified by column chromatography (1:1 
EtOAc/hexane) to give 0.21 g (66 %) white amorphous solid. Rf = 0.20 (1:1 EtOAc/hexane); 
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[α]D = +29 (c 0.56, CHCl3); 1H NMR (400 MHz, CDCl3) δ (ppm): 8.01 (2H, dd, J = 8.2, 1.1 
Hz, aromatics), 7.93 (2H, dd, J = 8.2, 1.0, aromatics), 7.88–7.80 (4H, m, aromatics), 7.52–
7.22 (12H, m, aromatics), 6.11 (1H, pseudo t, J = 9.6 Hz, H-2’ or H-3’ or H-4’), 6.06 (1H, 
pseudo t, J = 9.6 Hz, H-2’ or H-3’ or H-4’), 5.87 (1H, pseudo t, J = 9.5 Hz, H-2’ or H-3’ or H-
4’), 5.00 (1H, d, J = 9.4 Hz, H-1’), 4.66 (1H, dd, J = 12.3, 2.9 Hz, H-6’a), 4.57 (1H, dd, J = 
12.3, 5.1 Hz, H-6’b), 4.35 (1H, ddd, J = 9.6, 5.0, 3.2 Hz, H-5’), 4.32–4.27 (1H, m, CH2), 
4.22–4.14 (2H, m, CH2), 3.91–3.85 (1H, m, CH2), 1.25 (9H, s, C(CH3)3 ); 13C NMR (100 
MHz, CDCl3) δ (ppm): 166.2, 165.8, 165.4, 165.2 (C=O), 163.3, 156.7 (triazole C-3, C-5), 
133.4–128.3 (aromatics), 76.8, 74.8, 74.2, 72.2, 69.8 (C-1’–C-5’), 63.6 (C-6’), 60.8, 52.6 (2 × 
CH2), 32.4 (C(CH3)3), 29.1 (C(CH3)3). ESI-MS positive mode (m/z): calcd for C42H42N3O10 
([M+H]+): 748.287. Found: 748.35. Anal. Calcd for C42H41N3O10: C, 67.46; H, 5.53; N, 5.62. 
Found: C, 67.78; H, 5.80; N, 5.79. 
 
3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-5-benzyl-1,2,4-triazole (30) 
Prepared from compound 15 (0.30 g, 0.39 mmol) and hydrazinium acetate (44 mg, 0.48 
mmol) according to general procedure IV. Purified by column chromatography (1:2 
EtOAc/hexane) to give 0.22 g (75 %) white amorphous solid. Rf = 0.45 (2:1 Acetone/hexane); 
[α]D = +15 (c 0.54, CHCl3); 1H NMR (360 MHz, CDCl3) δ (ppm): 7.94–7.90 (4H, m, 
aromatics), 7.79–7.77 (4H, m, aromatics), 7.50–7.07 (17H, m, aromatics), 6.19 (1H, pseudo t, 
J = 9.7 Hz, H-2’ or H-3’ or H-4’), 6.05 (1H, pseudo t, J = 9.5 Hz, H-2’ or H-3’ or H-4’), 5.91 
(1H, pseudo t, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 5.12 (1H, d, J = 9.9 Hz, H-1’), 4.56–4.54 
(2H, m, H-6’a, H-6’b), 4.59 (1H, dd, J = 12.3, 5.0 Hz, H-6’b), 4.38–4.33 (1H, m, H-5’), 4.02 
(2H, s, PhCH2); 
13C NMR (90 MHz, CDCl3) δ (ppm): 166.4, 166.1, 165.3, 165.1 (C=O), 
158.4, 157.8 (triazole C-3, C-5), 135.7 (q, Ph), 133.5–127.2 (aromatics), 76.9, 74.6, 74.4, 
71.5, 69.8 (C-1’–C-5’), 63.6 (C-6’), 33.2 (PhCH2). ESI-MS negative mode (m/z): calcd for 
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C43H34N3O9 ([M-H]
-): 736.229. Found: 736.23. Anal. Calcd for C43H35N3O9: C, 70.01; H, 
4.78; N, 5.70. Found: C, 70.22; H, 4.87; N, 5.75. 
 
3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-5-benzyl-1-phenyl-1,2,4-triazole (31) 
Prepared from compound 15 (0.28 g, 0.37 mmol) and phenylhydrazine (44 µL, 0.45 mmol) 
according to general procedure IV. Purified by column chromatography (1:3 EtOAc/hexane) 
to give 0.21 g (71 %) pale orange amorphous solid. Rf = 0.38 (1:1 Acetone/hexane); [α]D = +4 
(c 0.54, CHCl3);
 1H NMR (400 MHz, CDCl3) δ (ppm): 8.03–8.00 (2H, m, aromatics), 7.94–
7.92 (2H, m, aromatics), 7.89–7.83 (4H, m, aromatics), 7.51–7.24 (16H, m, aromatics), 7.10–
7.04 (5H, m, aromatics), 6.95 (2H, dd, J = 7.4, 1.9 Hz, aromatics), 6.25 (1H, pseudo t, J = 9.8 
Hz, H-2’ or H-3’ or H-4’), 6.08 (1H, pseudo t, J = 9.5 Hz, H-2’ or H-3’ or H-4’), 5.91 (1H, 
pseudo t, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 5.12 (1H, d, J = 9.9 Hz, H-1’), 4.68 (1H, dd,  J = 
12.3, 3.1 Hz, H-6’a), 4.60 (1H, dd, J = 12.3, 5.1 Hz, H-6’b), 4.39 (1H, ddd, J = 9.7, 4.9, 3.2 
Hz, H-5’), 4.10 (1H, d, J = 15.8 Hz, PhCH2), 4.19 (1H, d, J = 15.8 Hz, PhCH2); 13C NMR 
(100 MHz, CDCl3) δ (ppm): 166.3, 166.0, 165.3, 164.7 (C=O), 158.8, 155.4 (triazole C-3, C-
5), 136.9, 135.5 (q, Ph), 133.4–125.1 (aromatics), 76.9, 74.7, 74.5, 71.7, 69.9 (C-1’–C-5’), 
63.7 (C-6’), 32.5 (PhCH2). ESI-MS positive mode (m/z): calcd for C49H40N3O9 ([M+H]+): 
814.276. Found: 814.28. Anal. Calcd for C49H39N3O9: C, 72.31; H, 4.83; N, 5.16. Found: C, 
70.57; H, 4.98; N, 5.10. 
 
3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-5-benzyl-1-(2-hydroxyethyl)-1,2,4-
triazole (32) 
Prepared from compound 15 (0.31 g, 0.41 mmol) and 2-hydroxyethylhydrazine (33 µL, 0.49 
mmol) according to general procedure IV. Purified by column chromatography (1:3 
EtOAc/hexane) to give 0.23 g (72 %) pale yellow amorphous solid. Rf = 0.42 (1:1 
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Acetone/hexane); [α]D = +16 (c 0.53, CHCl3); 1H NMR (400 MHz, CDCl3) δ (ppm): 8.00 (2H, 
d, J = 7.5 Hz, aromatics), 7.93 (2H, d, J = 7.4 Hz, aromatics), 7.86–7.81 (4H, m, aromatics), 
7.50–7.23 (12H, m, aromatics), 7.14–7.13 (3H, m, aromatics), 7.02–6.99 (2H, m, aromatics), 
6.10–6.06 (2H, m, H-2’ and/or H-3’ and/or H-4’), 5.87 (1H, pseudo t, J = 9.5 Hz, H-2’ or H-
3’ or H-4’), 5.04 (1H, d, J = 9.7 Hz, H-1’), 4.65 (1H, dd,  J = 12.2, 2.8 Hz, H-6’a), 4.57 (1H, 
dd, J = 12.2, 5.2 Hz, H-6’b), 4.36 (1H, ddd, J = 9.6, 5.0, 3.1 Hz, H-5’), 4.11 (2H, q, J = 16.1 
Hz, PhCH2), 3.94–3.89 (2H, m, CH2), 3.84–3.80 (1H, m, CH2), 3.66–3.62 (1H, m, CH2); 13C 
NMR (100 MHz, CDCl3) δ (ppm): 166.3, 165.9, 165.3, 165.3 (C=O), 158.2, 155.8 (triazole 
C-3, C-5), 135.0 (q, Ph), 133.4–127.1 (aromatics), 76.8, 74.6, 74.2, 72.3, 69.8 (C-1’–C-5’), 
63.7 (C-6’), 60.5, 50.7 (2 × CH2), 32.0 (PhCH2). ESI-MS positive mode (m/z): calcd for 
C45H40N3O10 ([M+H]
+): 782.271. Found: 782.27. Anal. Calcd for C45H39N3O10: C, 69.13; H, 
5.03; N, 5.37. Found: C, 69.46; H, 5.17; N, 5.28. 
 
3-(β-D-Glucopyranosyl)-5-methyl-1-phenyl-1,2,4-triazole (33) 
From triazole 21 (0.27 g, 0.36 mmol) according to general procedure V. Purified by column 
chromatography (3:1 CHCl3/MeOH) to yield 0.08 g (70%) pale yellow syrup. Rf = 0.54 (7:3 
CHCl3/MeOH); [α]D = +16 (c 0.51, MeOH); 1H NMR (400 MHz, CD3OD) δ (ppm): 7.60–
7.52 (5H, m, aromatics), 4.37 (1H, d, J = 9.7 Hz, H-1’), 3.88 (1H, dd, J = 12.1, 1.9 Hz, H-
6’a), 3.78 (1H, pseudo t, J = 9.2 Hz, H-2’ or H-3’ or H-4’), 3.71 (1H, dd, J = 12.1, 5.0 Hz, H-
6’b), 3.53 (1H, pseudo t, J = 8.7 Hz, H-2’ or H-3’ or H-4’), 3.49 (1H, pseudo t, J = 8.9 Hz, H-
2’ or H-3’ or H-4’), 3.46–3.42 (1H, m, H-5’), 2.50 (3H, s, CH3); 13C NMR (100 MHz, 
CD3OD) δ (ppm): 161.8, 154.7 (triazole C-3, C-5), 138.4 (q, Ph), 130.7, 130.4, 126.0 
(aromatics), 82.3, 79.3, 76.8, 74.3, 71.3 (C-1’–C-5’), 62.9 (C-6’), 12.9 (CH3). ESI-MS 
positive mode (m/z): calcd for C15H20N3O5 ([M+H]
+): 322.140. Found: 322.33. Anal. Calcd 
for C15H19N3O5: C, 56.07; H, 5.96; N, 13.08. Found: C, 56.20; H, 6.09; N, 13.13. 
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3-(β-D-Glucopyranosyl)-1-(2-hydroxyethyl)-5-methyl-1,2,4-triazole (34)  
From triazole 22 (0.24 g, 0.34 mmol) according to general procedure V. Purified by column 
chromatography (7:3 CHCl3/MeOH) to yield 0.07 g (72%) colourless syrup. Rf = 0.21 (7:3 
CHCl3/MeOH); [α]D = +16 (c 0.73, MeOH); 1H NMR (400 MHz, CD3OD) δ (ppm): 4.28 
(1H, d, J = 9.7 Hz, H-1’), 4.19 (2H, t, J = 5.1 Hz, CH2), 3.90 (2H, t, J = 5.1 Hz, CH2), 3.86 
(1H, dd, J = 12.1, 1.9 Hz, H-6’a), 3.74–3.65 (2H, m, H-2’ or H-3’ or H-4’ and H-6’b), 3.53–
3.45 (2H, m, H-2’ and/or H-3’ and/or H-4’), 3.44–3.40 (1H, m, H-5’), 2.48 (3H, s, CH3); 13C 
NMR (100 MHz, CD3OD) δ (ppm): 161.0, 155.5 (triazole C-3, C-5), 82.2, 79.2, 76.8, 74.3, 
71.3 (C-1’–C-5’), 62.9 (C-6’), 61.3, 51.9 (2 × CH2), 11.8 (CH3). ESI-MS positive mode (m/z): 
calcd for C11H20N3O6 ([M+H]
+): 290.135. Found: 290.33. Anal. Calcd for C11H19N3O6: C, 
45.67; H, 6.62; N, 14.53. Found: C, 45.78; H, 6.70; N, 14.65. 
 
3-(β-D-Glucopyranosyl)-5-hydroxymethyl-1-phenyl-1,2,4-triazole (35) 
From triazole 25 (0.21 g, 0.27 mmol) according to general procedure V. Purified by column 
chromatography (4:1 CHCl3/MeOH) to yield 0.08 g (84%) pale yellow syrup. Rf = 0.35 (3:1 
CHCl3/MeOH); [α]D = +18 (c 0.54, MeOH); 1H NMR (400 MHz, CD3OD) δ (ppm): 7.66–
7.63 (2H, m, aromatics), 7.60–7.50 (3H, m, aromatics), 4.67 (2H, s, CH2), 4.44 (1H, d, J = 9.7 
Hz, H-1’), 3.88 (1H, dd, J = 12.2, 1.8 Hz, H-6’a), 3.82 (1H, pseudo t, J = 9.2 Hz, H-2’ or H-3’ 
or H-4’), 3.71 (1H, dd, J = 12.1, 4.9 Hz, H-6’b), 3.63–3.45 (3H, m, H-2’ and/or H-3’ and/or 
H-4’, H-5’); 13C NMR (100 MHz, CD3OD) δ (ppm): 162.0, 156.6 (triazole C-3, C-5), 138.2 
(q, Ph), 130.5, 130.4, 125.7 (aromatics), 81.2, 79.3, 76.8, 74.2, 71.2 (C-1’–C-5’), 62.8 (C-6’), 
55.6 (CH2). ESI-MS positive mode (m/z): calcd for C15H20N3O6 ([M+H]
+): 338.340. Found: 
338.42. Anal. Calcd for C15H19N3O6: C, 53.41; H, 5.68; N, 12.46. Found: C, 53.49; H, 5.77; 
N, 12.52. 
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3-(β-D-Glucopyranosyl)-1-(2-hydroxyethyl)-5-hydroxymethyl-1,2,4-triazole (36)  
From triazole 26 (0.17 g, 0.24 mmol) according to general procedure V. Purified by column 
chromatography (4:1 CHCl3/MeOH) to yield 0.04 g (62%) colourless syrup. Rf = 0.29 (7:3 
CHCl3/MeOH); [α]D = +13 (c 0.53, MeOH); 1H NMR (360 MHz, CD3OD) δ (ppm): 4.76 
(2H, s, CH2), 4.36 (2H, t, J = 5.3 Hz, CH2), 4.31 (1H, d, J = 9.7 Hz, H-1’), 3.91 (2H, t, J = 5.3 
Hz, CH2), 3.84 (1H, dd, J = 12.1, 1.9 Hz, H-6’a), 3.74–3.64 (2H, m, H-2’ or H-3’ or H-4’, H-
6’b), 3.52–3.38 (3H, m, H-2’ and/or H-3’ and/or H-4’, H-5’); 13C NMR (90 MHz, CD3OD) δ 
(ppm): 161.3, 157.5 (triazole C-3, C-5), 82.2, 79.3, 76.9, 74.3, 71.4 (C-1’–C-5’), 62.9 (C-6’), 
61.3, 55.9, 52.3 (3 × CH2). ESI-MS positive mode (m/z): calcd for C11H20N3O7 ([M+H]+): 
306.295. Found: 306.33. Anal. Calcd for C11H19N3O7: C, 43.28, H, 6.27; N, 13.76. Found: C, 
43.41; H, 6.39; N, 13.71. 
 
5-(tert-Butyl)-3-(β-D-glucopyranosyl)-1-phenyl-1,2,4-triazole (37) 
From triazole 28 (0.13 g, 0.17 mmol) according to general procedure V. Purified by column 
chromatography (6:1 CHCl3/MeOH) to yield 0.03 g (50%) colourless syrup. Rf = 0.32 (5:1 
CHCl3/MeOH); [α]D = +8 (c 0.52, MeOH); 1H NMR (360 MHz, CD3OD) δ (ppm): 7.61–7.54 
(3H, m, aromatics), 7.49–7.44 (2H, m, aromatics), 4.34 (1H, d, J = 9.7 Hz, H-1’), 4.20 (2H, s, 
PhCH2), 3.86 (1H, dd, J = 12.1, 1.8 Hz, H-6’a), 3.78 (1H, pseudo t, J = 9.2 Hz, H-2’ or H-3’ 
or H-4’), 3.69 (1H, dd, J = 12.1, 4.9 Hz, H-6’b), 3.54–3.40 (3H, m, H-2’ and/or H-3’ and/or 
H-4’, H-5’), 1.27 (9H, s, C(CH3)3 ); 13C NMR (90 MHz, CD3OD) δ (ppm): 165.4, 160.8 
(triazole C-3, C-5), 140.7 (q, Ph), 131.4, 130.3, 129.3 (aromatics), 82.3, 79.4, 76.9, 74.2, 71.3 
(C-1’–C-5’), 62.9 (C-6’), 34.7 (C(CH3)3), 30.3 (C(CH3)3). ESI-MS positive mode (m/z): calcd 
for C18H26N3O5 ([M+H]
+): 364.423. Found: 364.42. Anal. Calcd for C18H25N3O5: C, 59.49; H, 
6.93; N, 11.56. Found: C, 59.57; H, 6.90; N, 11.70. 
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5-(tert-Butyl)-3-(β-D-glucopyranosyl)-1-(2-hydroxyethyl)-1,2,4-triazole (38) 
From triazole 29 (0.22 g, 0.29 mmol) according to general procedure V. Purified by column 
chromatography (5:1 CHCl3/MeOH) to yield 0.07 g (65%) white amorphous solid. Rf = 0.25 
(5:1 CHCl3/MeOH); [α]D = +10 (c 0.59, MeOH); 1H NMR (400 MHz, CD3OD) δ (ppm):, 
4.36 (2H, t, J = 5.6 Hz, CH2), 4.28 (1H, d, J = 9.8 Hz, H-1’), 4.00 (2H, t, J = 5.6 Hz, CH2), 
3.84 (1H, dd, J = 12.0, 1.9 Hz, H-6’a), 3.75 (1H, pseudo t, J = 9.2 Hz, H-2’ or H-3’ or H-4’), 
3.67 (1H, dd, J = 12.0, 5.0 Hz, H-6’b), 3.50–3.36 (3H, m, H-2’ and/or H-3’ and/or H-4’, H-
5’), 1.47 (9H, s, C(CH3)3 ); 13C NMR (100 MHz, CD3OD) δ (ppm): 164.9, 160.3 (triazole C-
3, C-5), 82.1, 79.2, 76.9, 74.1, 71.3 (C-1’–C-5’), 62.8 (C-6’), 61.3, 53.5 (2 × CH2), 33.8 
(C(CH3)3), 29.8 (C(CH3)3). ESI-MS positive mode (m/z): calcd for C14H26N3O6 ([M+H]
+): 
332.377. Found: 332.42. Anal. Calcd for C14H25N3O6: C, 50.75; H, 7.60; N, 12.68. Found: C, 
50.70; H, 7.53; N, 12.72. 
 
5-Benzyl-3-(β-D-glucopyranosyl)-1,2,4-triazole (39)  
From triazole 30 (0.18 g, 0.24 mmol) according to general procedure V. (The mixture was 
neutralised with acetic acid.) Purified by column chromatography (5:1 CHCl3/MeOH) to yield 
0.03 g (45%) colourless syrup. Rf = 0.34 (7:3 CHCl3/MeOH); [α]D = +10 (c 0.53, MeOH); 1H 
NMR (360 MHz, CD3OD) δ (ppm): 7.31–7.22 (5H, m, aromatics), 4.37 (1H, d, J = 9.2 Hz, H-
1’), 4.10 (2H, s, PhCH2), 3.85 (1H, dd, J = 12.0, 1.4 Hz, H-6’a), 3.68 (2H, H-2’ or H-3’ or H-
4’ or H-5’, H-6’b), 3.51–3.38 (3H, m, H-2’ and/or H-3’ and/or H-4’ and/or H-5’); 13C NMR 
(90 MHz, CD3OD) δ (ppm): 162.9, 157.7 (triazole C-3, C-5), 137.6 (q, Ph), 129.7, 128.0 
(aromatics), 82.2, 79.3, 76.8, 74.3, 71.3 (C-1’–C-5’), 62.8 (C-6’), 33.5 (PhCH2). ESI-MS 
positive mode (m/z): calcd for C15H20N3O5 ([M+H]
+): 322.140. Found: 322.33. Anal. Calcd 
for C15H19N3O5: C, 56.07; H, 5.96; N, 13.08. Found: C, 56.14; H, 5.99; N, 13.25. 
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5-Benzyl-3-(β-D-glucopyranosyl)-1-phenyl-1,2,4-triazole (40) 
From triazole 31 (0.170 g, 0.21 mmol) according to general procedure V. Purified by column 
chromatography (5:1 CHCl3/MeOH) to yield 0.06 g (70%) pale yellow syrup. Rf = 0.55 (7:3 
CHCl3/MeOH); [α]D = +11 (c 0.53, MeOH); 1H NMR (400 MHz, CD3OD) δ (ppm): 7.52–
7.49 (3H, m, aromatics), 7.52–7.49 (3H, m, aromatics), 7.25–7.18 (3H, m, aromatics),7.07–
7.03 (2H, m, aromatics), 4.42 (1H, d, J = 9.7 Hz, H-1’), 4.19 (2H, s, PhCH2), 3.89 (1H, dd, J 
= 12.1, 1.8 Hz, H-6’a), 3.83 (1H, pseudo t, J = 9.2 Hz, H-2’ or H-3’ or H-4’), 3.72 (1H, dd, J 
= 12.1, 5.0 Hz, H-6’b), 3.58–3.45 (3H, m, H-2’ and/or H-3’ and/or H-4’, H-5’); 13C NMR 
(100 MHz, CD3OD) δ (ppm): 162.1, 156.8 (triazole C-3, C-5), 138.2, 136.9 (q, Ph), 130.7, 
130.6, 129.7, 129.5, 128.1, 126.7 (aromatics), 82.3, 79.4, 76.9, 74.3, 71.3 (C-1’–C-5’), 62.9 
(C-6’), 33.1 (PhCH2). ESI-MS positive mode (m/z): calcd for C21H24N3O5 ([M+H]+): 
398.171. Found: 398.42. Anal. Calcd for C21H23N3O5: C, 63.47; H, 5.83; N, 10.57. Found: C, 
63.69; H, 5.90; N, 10.56. 
 
5-Benzyl-3-(β-D-glucopyranosyl)-1-(2-hydroxyethyl)-1,2,4-triazole (41) 
From triazole 32 (0.23 g, 0.29 mmol) according to general procedure V. Purified by column 
chromatography (5:1 CHCl3/MeOH) to yield 0.06 g (51%) colourless syrup. Rf = 0.34 (7:3 
CHCl3/MeOH); [α]D = +6 (c 0.53, MeOH); 1H NMR (400 MHz, CD3OD) δ (ppm): 7.35–7.23 
(5H, m, aromatics), 4.32 (1H, d, J = 9.7 Hz, H-1’), 4.26 (2H, s, PhCH2), 4.16 (2H, t, J = 5.3 
Hz, CH2), 3.87 (1H, dd, J = 12.3, 2.0 Hz, H-6’a), 3.83 (2H, t, J = 5.3 Hz, CH2), 3.75 (1H, 
pseudo t, J = 9.2 Hz, H-2’ or H-3’ or H-4’), 3.69 (1H, dd, J = 12.1, 5.0 Hz, H-6’b), 3.54–3.44 
(2H, m, H-2’ and/or H-3’ and/or H-4’), 3.44–3.40 (1H, m, H-5’); 13C NMR (100 MHz, 
CD3OD) δ (ppm): 161.5, 157.4 (triazole C-3, C-5), 137.0 (q, Ph), 129.9, 129.7, 128.1 
(aromatics), 82.3, 79.3, 76.9, 74.3, 71.3 (C-1’–C-5’), 62.9 (C-6’), 61.1, 52.0 (2 × CH2), 32.6 
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(PhCH2). ESI-MS positive mode (m/z): calcd for C17H24N3O6 ([M+H]
+): 366.166. Found: 
366.33. Anal. Calcd for C17H23N3O6: C, 55.88, H, 6.35; N, 11.50. Found: C, 56.00; H, 6.42; 
N, 11.44. 
 
5-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-3-methyl-1-phenyl-1,2,4-triazole (42) 
Prepared from compound 18 (0.14 g, 0.21 mmol) and phenylhydrazine (25 µL, 0.25 mmol) 
according to general procedure IV. Purified by column chromatography (1:3 EtOAc/hexane) 
to give 0.10 g (65 %) yellow amorphous solid. Rf = 0.29 (1:2 EtOAc/hexane); [α]D = +47 (c 
0.345, CHCl3);
 1H NMR (360 MHz, CDCl3) δ (ppm): 8.05 (2H, dd, J = 8.2, 1.3 Hz, 
aromatics), 7.91 (2H, dd, J = 8.2, 1.4 Hz, aromatics), 7.82 (2H, dd, J = 8.2, 1.4 Hz, 
aromatics), 7.73 (2H, dd, J = 8.2, 1.3, aromatics), 7.88–7.80 (4H, m, aromatics), 7.59–7.25 
(17H, m, aromatics), 6.21 (pseudo t, 1H, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 5.91 (1H, pseudo 
t, J = 9.5 Hz, H-2’ or H-3’ or H-4’), 5.70 (1H, pseudo t, J = 9.5 Hz, H-2’ or H-3’ or H-4’), 
4.96 (1H, d, J = 9.9 Hz, H-1’), 4.70 (1H, dd, J = 12.3, 2.7 Hz, H-6’a), 4.46 (1H, dd, J = 12.3, 
6.4 Hz, H-6’b), 4.27 (1H, ddd, J = 12.3, 6.4, 2.7 Hz, H-5’), 2.37 (3H, s, CH3); 13C NMR (90 
MHz, CDCl3) δ (ppm): 166.2, 165.9, 165.3, 164.3 (C=O), 161.1, 150.1 (triazole C-3, C-5), 
136.9–125.1 (aromatics), 77.0, 74.3, 71.5, 71.0, 69.6 (C-1’–C-5’), 63.6 (C-6’), 13.9 (CH3). 
ESI-MS positive mode (m/z): calcd for C43H36N3O9 ([M+H]
+): 738.245. Found: 738.29. Anal. 
Calcd for C43H35N3O9: C, 70.01; H, 4.78; N, 5.70. Found: C, 70.19; H, 4.90; N, 5.63.  
 
3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-5-phenyl-1,2,4-triazole (43) 
Prepared from compound 19 (0.10 g, 0.13 mmol) hydrazinium acetate (14 mg, 0.16 mmol) 
according to general procedure IV. Purification by column chromatography (1:2 
EtOAc/hexane) yielded 0.03 g (35 %) white solid. The compound characterization data are 
identical with those reported 20. 
36 
 
 
5-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-1,3-diphenyl-1,2,4-triazole (44) 
Prepared from compound 19 (0.15 g, 0.20 mmol) and phenylhydrazine (24 µL, 0.24 mmol) 
according to general procedure IV. Purified by column chromatography (1:3 EtOAc/hexane) 
to give 0.14 g (90 %) yellow amorphous solid. Rf = 0.49 (1:2 EtOAc/hexane); [α]D = +19 (c 
0.38, CHCl3);
 1H NMR (360 MHz, CDCl3) δ (ppm): 8.09-8.05 (4H, m, aromatics), 7.93 (2H, 
d, J = 7.5 Hz, aromatics), 7.85 (2H, d, J = 7.5 Hz, aromatics), 7.72 (2H, d, J = 7.5 Hz, 
aromatics), 7.64 (2H, d, J = 7.5 Hz, aromatics), 7.59–7.21 (18H, m, aromatics), 6.42 (pseudo 
t, 1H, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 5.95 (1H, pseudo t, J = 9.5 Hz, H-2’ or H-3’ or H-
4’), 5.73 (1H, pseudo t, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 5.00 (1H, d, J = 9.9 Hz, H-1’), 4.72 
(1H, dd, J = 12.2, 2.0 Hz, H-6’a), 4.46 (1H, dd, J = 12.2, 6.6 Hz, H-6’b), 4.30 (1H, ddd, J = 
12.2, 6.6, 2.0 Hz, H-5’); 13C NMR (90 MHz, CDCl3) δ (ppm): 166.2, 166.0, 165.4, 164.5 
(C=O), 162.1, 150.6 (triazole C-3, C-5), 137.1–125.1 (aromatics), 77.1, 74.4, 71.7, 70.7, 69.7 
(C-1’–C-5’), 63.7 (C-6’). ESI-MS positive mode (m/z): calcd for C48H38N3O9 ([M+H]+): 
800.261. Found: 800.26. Anal. Calcd for C48H37N3O9: C, 72.08; H, 4.66; N, 5.25. Found: C, 
70.22; H, 4.73; N, 5.24. 
 
5-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-1-(2-hydroxyethyl)-3-phenyl-1,2,4-
triazole (45) 
Prepared from compound 19 (0.10 g, 0.13 mmol) and 2-hydroxyethylhydrazine (10 µL, 0.15 
mmol) according to general procedure IV. Purified by column chromatography (1:2 
EtOAc/hexane) to give 0.09 g (90 %) yellow amorphous solid. Rf = 0.45 (1:1 EtOAc/hexane); 
[α]D = +4 (c 0.305, CHCl3); 1H NMR (360 MHz, CDCl3) δ (ppm): ): 8.09 (2H, dd, J = 8.4, 1.4 
Hz, aromatics), 7.97 (2H, dd, J = 8.3, 1.2 Hz, aromatics), 7.89 (2H, dd, J = 8.3, 1.2 Hz, 
aromatics), 7.80 (2H, dd, J = 8.4, 1.4 Hz, aromatics), 7.74 (2H, dd, J = 7.6, 2.1 Hz, 
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aromatics), 7.60–7.24 (15H, m, aromatics), 6.11 (pseudo t, 1H, J = 9.6 Hz, H-2’ or H-3’ or H-
4’), 5.95 (1H, pseudo t, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 5.87 (1H, pseudo t, J = 9.8 Hz, H-
2’ or H-3’ or H-4’), 5.27 (1H, d, J = 9.9 Hz, H-1’), 4.79 (1H, dd, J = 12.4, 2.7 Hz, H-6’a), 
4.65 (1H, ddd, J = 14.2, 7.6, 3.1 Hz, CH2), 4.51 (1H, dd, J = 12.4, 4.7 Hz, H-6’b), 4.42–4.29 
(2H, m, H-5’ and CH2), 4.11–4.03 (1H, m, CH2), 3.92 (ddd, J = 12.3, 5.7, 3.1 Hz, 1H, CH2), 
3.52 (br s, 1H, OH); 13C NMR (90 MHz, CDCl3) δ (ppm): 166.1, 165.8, 165.5, 165.2 (C=O), 
161.3, 150.8 (triazole C-3, C-5), 133.6–126.2 (aromatics), 77.2, 73.9, 73.5, 71.5, 71.4, 68.9 
(C-1’–C-5’, CH2), 64.8 (C-6’), 61.4 (CH2). ESI-MS positive mode (m/z): calcd for 
C44H38N3O10 ([M+H]
+): 768.256. Found: 768.28. Anal. Calcd for C44H37N3O10: C, 68.83; H, 
4.86; N, 5.47. Found: C, 68.96; H, 4.99; N, 5.60. 
 
5-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-1-(tert-butyl)-3-phenyl-1,2,4-triazole 
(46) 
Prepared from compound 19 (0.15 g, 0.20 mmol) and tert-butylhydrazine hydrochloride (0.03 
g, 0.24 mmol) according to general procedure IV. Purified by column chromatography (1:2 
EtOAc/hexane) to give 0.09 g (60 %) yellow amorphous solid. Rf = 0.57 (1:2 EtOAc/hexane); 
[α]D = +12 (c 0.485, CHCl3); 1H NMR (360 MHz, CDCl3) δ (ppm): 8.04–7.87 (8H, m, 
aromatics), 7.75 (2H, d, J = 7.4 Hz, aromatics), 7.58–7.22 (15H, m, aromatics), 6.59 (pseudo 
t, 1H, J = 9.6 Hz, H-2’ or H-3’ or H-4’), 6.04 (1H, pseudo t, J = 9.6 Hz, H-2’ or H-3’ or H-
4’), 5.74 (1H, pseudo t, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 5.25 (1H, d, J = 9.7 Hz, H-1’), 4.65 
(1H, dd, J = 12.3, 2.5 Hz, H-6’a), 4.49 (1H, dd, J = 12.2, 6.9 Hz, H-6’b), 4.38 (1H, ddd, J = 
9.8, 6.9, 2.6 Hz, H-5’), 1.71 (9H, s, C(CH3)3 ); 13C NMR (90 MHz, CDCl3) δ (ppm): 166.2, 
166.2, 165.4, 164.6 (C=O), 159.0, 149.8 (triazole C-3, C-5), 133.7–126.3 (aromatics), 76.9, 
74.6, 72.6, 71.1, 69.8 (C-1’–C-5’), 63.9 (C-6’), 61.2 (C(CH3)3), 30.3 (C(CH3)3). ESI-MS 
positive mode (m/z): calcd for C46H42N3O9 ([M+H]
+): 780.292. Found: 780.32. Anal. Calcd 
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for C46H41N3O9: C, 70.85, H, 5.30; N, 5.39. Found: C, 70.97; H, 5.41; N, 5.34. 
 
5-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-1-(3-chlorophenyl)-3-phenyl-1,2,4-
triazole (47) 
Prepared from compound 19 (0.15 g, 0.20 mmol) and 3-chlorophenylhydrazine hydrochloride 
(0.04 g, 0.24 mmol) according to general procedure IV. Purified by column chromatography 
(1:3 EtOAc/hexane) to give 0.12 g (72 %) yellow amorphous solid. Rf = 0.50 (1:2 
EtOAc/hexane); [α]D = +27 (c 0.425, CHCl3); 1H NMR (360 MHz, CDCl3) δ (ppm): 8.10–
8.00 (4H, m, aromatics), 7.93 (2H, d, J = 7.4 Hz, aromatics), 7.86 (2H, d, J = 7.4 Hz, 
aromatics), 7.77–7.65 (3H, m, aromatics), 7.60–7.21 (18H, m, aromatics), 6.39 (pseudo t, 1H, 
J = 9.7 Hz, H-2’ or H-3’ or H-4’), 5.97 (1H, pseudo t, J = 9.6 Hz, H-2’ or H-3’ or H-4’), 5.76 
(1H, pseudo t, J = 9.7 Hz, H-2’ or H-3’ or H-4’), 5.01 (1H, d, J = 9.8 Hz, H-1’), 4.72 (1H, dd, 
J = 12.4, 2.6 Hz, H-6’a), 4.46 (1H, dd, J = 12.3, 6.3 Hz, H-6’b), 4.33 (1H, ddd, J = 9.4, 6.3, 
2.7 Hz, H-5’); 13C NMR (90 MHz, CDCl3) δ (ppm): 166.2, 166.0, 165.3, 164.6 (C=O), 162.3, 
150.7 (triazole C-3, C-5), 138.1–122.8 (aromatics), 77.1, 74.2, 71.8, 70.7, 69.5 (C-1’–C-5’), 
63.5 (C-6’). ESI-MS positive mode (m/z): calcd for C48H37ClN3O9 ([M+H]+): 834.222. 
Found: 834.26. Anal. Calcd for C48H36ClN3O9: C, 69.11; H, 4.35; N, 5.04. Found: C, 69.26; 
H, 4.32; N, 5.15. 
 
5-(β-D-Glucopyranosyl)-3-methyl-1-phenyl-1,2,4-triazole (48) 
From triazole 42 (0.10 g, 0.14 mmol) according to general procedure V. Purified by column 
chromatography (18:1 CHCl3/MeOH) to yield 0.04 g (96%) white amorphous solid. Rf = 0.27 
(9:1 CHCl3/MeOH); [α]D = +7 (c 0.31, MeOH); 1H NMR (360 MHz, CD3OD) δ (ppm): 7.61–
7.50 (5H, m, aromatics), 4.30 (1H, d, J = 9.6 Hz, H-1’), 3.91–3.82 (2H, m, H-2’ or H-3’ or H-
4’ and H-6’a), 3.67 (1H, dd, J = 12.1, 5.2 Hz, H-6’b), 3.49 (1H, pseudo t, J = 9.3 Hz, H-2’ or 
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H-3’ or H-4’), 3.40 (1H, pseudo t, J = 9.0 Hz, H-2’ or H-3’ or H-4’), 3.31–3.28 (1H, m, H-5’), 
2.42 (3H, s, CH3); 
13C NMR (90 MHz, CD3OD) δ (ppm): 160.9, 154.1 (triazole C-3, C-5), 
137.2 (q, Ph), 130.1, 130.1, 126.0 (aromatics), 81.5, 78.6, 73.4, 72.8, 70.3 (C-1’–C-5’), 62.2 
(C-6’), 13.6 (CH3). ESI-MS positive mode (m/z): calcd for C15H19N3NaO5 ([M+Na]+): 
344.122. Found: 344.12. Anal. Calcd for C15H19N3O5: C, 56.07; H, 5.96; N, 13.08. Found: C, 
56.20; H, 6.03; N, 13.01. 
 
5-(β-D-Glucopyranosyl)-1,3-diphenyl-1,2,4-triazole (49) 
From triazole 44 (0.14 g, 0.18 mmol) according to general procedure V. Purified by column 
chromatography (18:1 CHCl3/MeOH) to yield 0.05 g (83%) white amorphous solid. Rf = 0.28 
(9:1 CHCl3/MeOH); [α]D = +7 (c 0.47, MeOH); 1H NMR (360 MHz, CD3OD) δ (ppm):  
8.09–8.06 (2H, m, aromatics), 7.70–7.67 (2H, m, aromatics), 7.55–7.50 (3H, m, aromatics), 
7.45–7.39 (3H, m, aromatics), 4.40 (1H, m, H-1’), 4.00 (1H, pseudo t, J = 9.3 Hz, H-2’ or H-
3’ or H-4’), 3.81 (1H, dd, J = 12.1, 2.5 Hz, H-6’a), 3.71 (1H, dd, J = 12.4, 4.4 Hz, H-6’b), 
3.61 (1H, pseudo t, J = 9.3 Hz, H-2’ or H-3’ or H-4’), 3.45 (1H, pseudo t, J = 9.1 Hz, H-2’ or 
H-3’ or H-4’), 3.32 (1H, ddd, J = 9.7, 4.4, 2.5 Hz, H-5’); 13C NMR (90 MHz, CD3OD) δ 
(ppm): 162.1, 154.5 (triazole C-3, C-5), 137.1, 130.1 (q, Ph), 130.0, 129.8, 129.0, 126.9, 
125.9 (aromatics), 80.9, 78.1, 73.2, 72.7, 69.7 (C-1’–C-5’), 61.7 (C-6’). ESI-MS positive 
mode (m/z): calcd for C20H21N3NaO5 ([M+Na]
+): 406.138. Found: 406.17. Anal. Calcd for 
C20H21N3O5: C, 62.65; H, 5.52; N, 10.96. Found: C, 62.80; H, 5.48; N, 11.02. 
 
5-(β-D-Glucopyranosyl)-1-(2-hydroxyethyl)-3-phenyl-1,2,4-triazole (50) 
From triazole 45 (0.09 g, 0.14 mmol) according to general procedure V. Purified by column 
chromatography (9:1 CHCl3/MeOH) to yield 0.04 g (98%) white amorphous solid. Rf = 0.10 
(9:1 CHCl3/MeOH); [α]D = +1 (c 0.35, MeOH); 1H NMR (360 MHz, CD3OD) δ (ppm): 8.01 
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(2H, d, J = 6.5 Hz, aromatics), 7.43–7.38 (3H, m, aromatics), 4.67 (1H, d, J = 9.6 Hz, H-1’), 
4.49–4.33 (2H, m, H-2’ and/or H-3’ and/or H-4’), 4.00–3.95 (2H, m, CH2), 3.88 (1H, dd, J = 
12.2, 1.9 Hz, H-6’a), 3.79 (1H, t, J = 9.5 Hz, H-2’ or H-3’ or H-4’), 3.73 (1H, dd, J = 12.2, 
4.8 Hz, H-6’b), 3.58–3.52 (2H, m, CH2), 3.50–3.44 (1H, m, H-5’); 13C NMR (90 MHz, 
CD3OD) δ (ppm): 161.9, 155.9 (triazole C-3, C-5), 130.5 (q, Ph), 130.2, 129.4, 127.1 
(aromatics), 81.8, 78.8, 74.2, 73.8, 70.5 (C-1’–C-5’), 62.3 (C-6’), 61.3, 52.2 (2 × CH2). ESI-
MS positive mode (m/z): calcd for C16H21N3NaO6 ([M+Na]
+): 374.133. Found: 374.13. Anal. 
Calcd for C16H21N3O6: C, 54.70; H, 6.02; N, 11.96. Found: C, 54.85; H, 6.00; N, 12.04. 
 
1-(tert-Butyl)-5-(β-D-glucopyranosyl)-3-phenyl-1,2,4-triazole (51) 
From triazole 46 (0.09 g, 0.14 mmol) according to general procedure V. Purified by column 
chromatography (18:1 CHCl3/MeOH) to yield 0.04 g (99%) white amorphous solid. Rf = 0.23 
(9:1 CHCl3/MeOH); [α]D = +15 (c 0.295, MeOH); 1H NMR (360 MHz, CD3OD) δ (ppm): 
7.99 (2H, d, J = 6.7 Hz, aromatics), 7.40–7.34 (3H, m, aromatics), 4.66 (1H, d, J = 9.3 Hz, H-
1’), 4.08 (1H, pseudo t, J = 9.0 Hz, H-2’ or H-3’ or H-4’), 3.83 (1H, dd, J = 12.2, 2.5 Hz, H-
6’a), 3.75 (1H, dd, J = 12.3, 3.9 Hz, H-6’b), 3.68–3.54 (2H, m, H-2’ and/or H-3’ and/or H-4’), 
3.43–3.38 (1H, m, H-5’), 1.72 (9H, s, C(CH3)3 ); 13C NMR (90 MHz, CD3OD) δ (ppm): 
159.1, 153.3 (triazole C-3, C-5), 131.2 (q, Ph), 129.4, 128.8, 126.5, (aromatics), 80.7, 77.9, 
74.0, 73.2, 69.7 (C-1’–C-5’), 62.0 (C-6’), 61.7 (C(CH3)3), 30.5 (C(CH3)3). ESI-MS positive 
mode (m/z): calcd for C18H25N3NaO5 ([M+Na]
+): 386.170. Found: 386.17. Anal. Calcd for 
C18H25N3O5: C, 59.49; H, 6.93; N, 11.56. Found: C, 59.56; H, 6.90; N, 11.63. 
 
1-(3-Chlorophenyl)-5-(β-D-glucopyranosyl)-3-phenyl-1,2,4-triazole (52) 
From triazole 47 (0.12 g, 0.14 mmol) according to general procedure V. Purified by column 
chromatography (18:1 CHCl3/MeOH) to yield 0.06 g (99%) white amorphous solid. Rf = 0.26 
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(9:1 CHCl3/MeOH); [α]D = +9 (c 0.5, MeOH); 1H NMR (360 MHz, CD3OD) δ (ppm): 8.11–
8.03 (2H, m, aromatics), 7.76 (1H, s, aromatics), 7.68–7.63 (1H, m, aromatics), 7.50–7.38 
(5H, m, aromatics), 4.39 (1H, d, J = 9.6 Hz, H-1’), 4.02 (1H, pseudo t, J = 9.3 Hz, H-2’ or H-
3’ or H-4’), 3.85 (1H, dd, J = 12.2, 2.5 Hz, H-6’a), 3.74 (1H, dd, J = 12.3, 3.9 Hz, H-6’b), 
3.61 (1H, pseudo t, J = 9.3 Hz, H-2’ or H-3’ or H-4’), 3.48 (1H, pseudo t, J = 9.3 Hz, H-2’ or 
H-3’ or H-4’), 3.36 (1H, ddd, J = 9.8, 4.5, 2.5 Hz, H-5’); 13C NMR (90 MHz, CD3OD) δ 
(ppm): 162.4, 154.6 (triazole C-3, C-5), 138.2, 135.5 (q, Ph), 131.0 130.3, 130.3, 130.0, 
129.1, 126.9, 126.1, 124.1 (aromatics), 81.1, 78.2, 73.1, 72.8, 69.7 (C-1’–C-5’), 61.7 (C-6’). 
ESI-MS positive mode (m/z): calcd for C20H20ClN3NaO5 ([M+Na]
+): 440.099. Found: 440.10. 
Anal. Calcd for C20H20ClN3O5: C, 57.49; H, 4.82; N, 10.06. Found: C, 57.60; H, 4.80; N, 
10.11. 
 
Supporting information 
Copies of NMR spectra for the new compounds. 
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